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Abstract 
Nitrogen containing bisphosphonates (N-BPs) including zoledronate (ZOL) and alendronate 
(ALD) inhibit farnesyl diphosphate synthase, and have been shown to have a cytotoxic affect 
against cancer cells as a monotherapy and to also sensitise tumour cells to destruction by γδ T 
cells. γδ T cells are a subset of human T lymphocytes and have a diverse range of roles in the 
immune system including the recognition and destruction of cancer cells. This property of γδ 
T cells can be harnessed for use in cancer immunotherapy through in vivo expansion or the 
adoptive transfer of ex vivo activated γδ T cells. The use of N-BPs with γδ T cells has been 
shown to have a synergistic effect in in vitro, animal and clinical studies. 
N-BPs have limited in vivo activity due to rapid clearance from the circulation. By 
encapsulating N-BPs in liposomes (L) it is possible to increase the levels of N-BPs at non-
osseous tumour sites. L-ZOL and L-ALD have been shown to have different toxicological 
profiles than free ZOL or ALD. Both L-ALD and L-ZOL led to increased spleen weight, 
leucocytosis, neutrophilia and lymphocytopenia in mice after intravenous injection. L-ALD 
was shown to be better tolerated than L-ZOL in murine studies. Biodistribution studies have 
been performed in order to better understand the interaction of N-BPs and γδ T cells in vivo. 
Additionally, in vivo therapy studies have shown that mice treated with both L-ALD and γδ T 
cells had a significant reduction in tumour growth compared to mice treated with L-ALD or 
γδ T cells alone. The use of ligand-targeted liposomes may further increase the efficacy of 
this combinatory immunotherapy. Liposomes targeting the αvβ6 integrin receptor using the 
peptide A20FMDV2 had a greater ability than untargeted liposomes in sensitising cancer 
cells to destruction by γδ T cells in αvβ6 positive cancer cell lines.  
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1. Nitrogen-containing bisphosphonates 
1.1 Mechanism of Action of N-BPs 
While nitrogen-containing bisphosphonates (N-BPs) were originally used in the treatment of 
osteoporosis and other bone disorders [1], they have shown to have several clinical 
indications including cytotoxic activity as a monotherapy [2, 3] and activation of γδ T cells 
[4]. Bisphosphonates (BPs) are chemically stable analogue of pyrophosphate compounds 
found in nature. All BPs in clinical use consist of a core structure made up of P-C-P bonds 
which is resistant to enzymatic hydrolysis (Figure 1) [5].  
 
Figure 1: Structure of various bisphosphonates. Template structure of bisphosphonates 
and structure of zoledronate and other nitrogen-containing bisphosphonates discussed 
(Adapted from Stresing et al, 2007 [6]). 
 
Later generations of BPs led to in incorporation of nitrogen atoms into their structure, 
increasing their potency due to an additional mechanism of action [1]. N-BPs inhibits 
farnesyl diphosphate (FPP) synthase which is a key enzyme in the mevalonate biosynthetic 
pathway [7]. Inhibition of FPP synthase leads to the upstream accumulation of the 
triphosphoric acid 1-adenosin-5-yl ester 3-(3-methylbut-3-enyl) ester (Appp1) which then 
induces apoptosis via the inhibition of mitochondrial ADP/ATP translocase [8]. Inhibition of 
FPP synthase also prevents the prenylation of Guanosine triphosphate (GTP)-binding proteins 
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such as Ras, Rho and Rac leading to cell growth inhibition and can activate the caspase 
dependant mechanism of apoptosis [9].  
 
1.2 Anti-cancer activity of N-BPs 
BPs have also found clinical applications in the treatment of cancer. Both BPs and N-BPs are 
use in the treatment of multiple myeloma [10] and bone metastases from breast, lung, prostate 
and other solid tumour cancers [11]. They have shown to be effective in reducing skeletal-
related events associated with malignancies such as hypercalcaemia and increased bone 
destruction [12]. N-BPs have also shown to have anti-tumour activity in non-osseous tumours 
and have been shown to induce tumour apoptosis and inhibit tumour cell proliferation, 
migration and invasion. They also have anti-angiogenic effects and interfere with endothelial 
cell migration, proliferation and tube formation [6]. The use of ZOL and ALD as anti-cancer 
agents will be focused on in this review.  
 
ZOL is the most potent of the clinically used BPs. due to the presence of two nitrogen atoms 
contained within a heterocyclic ring structure [13].  ZOL has direct effects on tumour cells in 
vitro and has been shown to decrease the viability and proliferation of several cancer cell 
lines as well as inducing apoptosis of cancer cells. After exposure of the prostate cancer cell 
lines PC-3, DU-145, LNCaP and CRW22Rv1 to 100μM of ZOL, the autophagic and 
apoptotic proteins LC3-II and activated caspase-3 were detected showing that ZOL exposure 
resulted in cell death [14]. ZOL has also been shown to have a synergistic effect in vitro 
when used in combination with the cytotoxic agents; paclitaxel, etoposide and cisplatin [15].  
 
ZOL has been shown to inhibit progression of established bone metastases and development 
of new bone metastases in two models of breast cancer in mice [16]. Nude mice bearing 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
5 
 
MDA-MB-231 tumours were subcutaneously injected with 0.2, 1.0 or 5.0 μg/day of ZOL for 
10 consecutive days and were shown to have reductions in bone lesions of more than 80% 
compared to controls [16]. Treatment with 5 μg/day ZOL for seven days after injection of 
4T1 murine mammary tumour cells were shown to decrease the formation of new bone 
metastases [16]. Another study in a murine model of multiple myeloma has shown a 
reduction in osteolysis, tumour burden and angiogenesis with a subsequent increase in 
survival time [17]. ZOL has also shown to be effective in the treatment of soft tissue tumours 
in extra-osseous sites. It has been shown to reduce the growth of cervical tumours and the 
progression of premalignant lesions in a transgenic mouse model [18]. ZOL was shown to 
inhibit expression of the pro-angiogenic protease, matrix metalloproteinase 9 (MMP-9) by 
tumour associated macrophages.  
Clinically, ZOL has been used in several studies to determine its anti-cancer effects in 
humans. A phase II clinical study has shown that ZOL increases the clearance and reduces 
the number of disseminated tumour cells in the bone of patients with early breast cancer [2, 
3]. However, other studies have not shown the benefit of adjuvant ZOL treatment in early 
breast cancer [19]. A clinical trial of the use of ZOL in multiple myeloma, demonstrated 16 
% reduced mortality and an extended mean survival of 5.5 months when compared to the 
non-nitrogen containing BP, clodronate [20]. A Cochrane meta-analysis of other clinical 
trials confirmed the therapeutic efficacy of ZOL in myeloma patients [21]. ZOL has also 
shown to be effective in the treatment of malignancy-related skeletal issues in acute myeloid 
leukaemia [22] and lymphoma [23]. Additionally, prostate cancer patients treated with ZOL 
were shown to improved prostate-specific antigen progression-free survival time [24]. 
Various trials in patients with bone metastasis from solid malignancies have shown the 
benefit of ZOL therapy [25]. 
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ALD has also been shown to have anti-cancer activity in both in vitro and in vivo studies. 
When human umbilical vein endothelial cells (HUVEC) were treated with ALD, migration 
and formation of capillary-like structures were inhibited in vitro [26]. This is thought to be 
due to the inhibition of Rho geranylgeranylation. In vitro inhibition of migration of the 
prostate cancer cell lines PC-3 and Du-145 and the breast cancer cell lines MDA-MB-231 
after treatment with ALD has also been observed [27]. ALD inhibited the proliferation of the 
Huh-7 hepatocellular carcinoma cell lines in a time and dose dependant manner at 
concentrations between 5-20 μM [28]. ALD has also been shown to have anti-proliferative 
effect on the epidermoid carcinoma cell line A431, as well as inhibiting cell invasion in a 
matrigel invasion assay [29]. ALD downregulated MMP-2 in osteosarcoma cell lines, leading 
to inhibition of cell invasion [30]. ALD has been shown to have synergistic cytotoxic effect 
with simvastatin on PC-3 cells when used at low doses due to sequential blockade of the 
mevalonate pathway [31].  
 
ALD (0.5 mg/kg, s.c.) was shown to reduce tumour growth and decrease tumour metastasis to 
prostate-draining lymph nodes in an orthotopic PC3 nude mouse tumour model [32]. A 
decrease in the number of CD-34 positive endothelial cells and an increase in apoptotic cells 
in the tumour and lymph nodes was observed, suggesting both cytotoxic and anti-angiogenic 
effects. When nude mice inoculated with i.p. Caov-3 ovarian cancer cells were treated i.p. 
with ALD, an anti-tumour effect was observed [33]. Stromal invasion of the tumour was 
decreased and MMP-2 activity was inhibited in the ascites. In the same model, ALD 
treatment has also shown to reduce intra-tumour neo-angiogenesis in disseminated ovarian 
tumours of athymic mice [26]. In clinical studies, ALD has been shown to increase bone 
mineral density of the spine and hip in men with prostate cancer treated with androgen 
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deprivation therapy [34, 35].  However, the direct anti-tumour efficacy of ALD has not yet 
been studied in humans. 
 
1.3 Pharmacokinetics of BPs 
The anti-tumour efficacy of N-BPs for non-osseous tumours is limited by their 
pharmacokinetic properties. For example, although ZOL has been shown to have anti-tumour 
activity in vitro, its limited in vivo efficacy is probably due to its rapid renal clearance and 
accumulation in the bone [36]. When given orally, less than 1 % of N-BPs are absorbed [37] 
and this is decreased in the presence of food and drinks containing calcium, magnesium or 
aluminium [38]. BPs can be administered intravenously to circumvent their poor absorption. 
However, BPs that are not excreted renally bind rapidly to the bone [39]. N-BPs are not 
metabolised and are excreted unchanged mainly in the urine, with a small percentage 
excreted in the bile [39]. BPs that are adsorbed to the bone have a long half-life and are 
eliminated only when the bone is resorbed [40]. The short half-life in the blood and high 
affinity to the bone does not allow N-BPs to accumulate in tumours at concentrations 
necessary for therapeutic efficacy, either as a monotherapy or for use in γδ T cell 
immunotherapy. Nanoformulations of N-BPs aim to lower bone affinity and increase half-life 
in the blood circulation [41] and can dramatically change the biodistribution and 
pharmacological profile of N-BPs.  
 
2. Liposomes 
2.1 Introduction to liposomes 
Liposomes, a closed bilayer phospholipid system, were first described in 1965 [42]. They are 
defined as “phospholipid vesicles consisting of one or more concentric lipid bilayers 
enclosing discrete aqueous spaces” [43]. Liposomes have since been developed as a drug 
delivery system for many different therapeutic applications including delivery of cancer 
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chemotherapy, vaccines, gene therapy, antimicrobials, biomolecules and topical drug delivery 
as well as for use in diagnostic techniques [44]. Liposomes have been shown to overcome 
barriers to cellular and tissue uptake and improve stability and biodistribution profiles of 
therapeutic agents in vivo [43]. 
 
Liposomes were proposed as drug carriers in cancer therapy due to their ability to be 
preferentially taken up in tumours [45] and have been shown to enhance the efficacy and 
safety of chemotherapeutic agents [46]. Tumour vasculature inside tumours undergoing 
angiogenesis tend to exhibit leaky endothelial lining as rapid tumour growth leads to 
structural abnormalities. This results in blood vessels that are permeable to nanoparticles such 
as liposomes. This effect is further reinforced by the lack of efficient lymphatic drainage of 
the tumour which causes liposomes to accumulate preferentially in the tumour area. This is 
known as enhanced permeation and retention effect (EPR) as illustrated in Figure 2 [47].  
Particles of 10 – 500 nm are thought to be able to extravasate into tumours as the pore sizes 
in the endothelial lining of leaky blood vessels in peripheral tumours are estimated to be 400 
– 600 nm in diameter [48].  However, particles with diameters less than 200 nm have been 
shown to be more effective at accumulating in tumour sites. This passive tumour targeting 
does not occur in all tumours and vessel leakiness may also be heterogeneous within a single 
tumour [49]. Ligand-targeted or ‘active’ targeting of liposomes may result in liposomes that 
are more selective to cancer cells, once passive targeting has taken place [46].  
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Figure 2: The enhanced permeation and retention (EPR) effect. Tumour vasculature has 
increased permeability compared to healthy blood vessels.  Extravasation of nanoparticles 
through increased pores in vessel walls coupled with ineffective lymphatic drainage results in 
enhanced permeation and retention of the particles in tumours (EPR effect). Nanoparticles 
can be functionalised with ligands in active cellular targeting. The nanoparticles can (i) 
release their contents in close proximity to the target cells; (ii) attach to the membrane of the 
cell and act as an extracellular sustained-release drug depot; or (iii) internalise into the cell 
(adapted from Peer et al., 2007 [47]). 
Liposomes can be used to increase the therapeutic index of a drug whereby a greater amount 
of the active drug reaches the tumour cell leading to an increased cytotoxic effect while at the 
same time side effects are reduced because of drug encapsulation [50].  
 
2.2 ZOL nanoformulations 
Many different nanoformulations of ZOL have been formulated and their in vitro and in vivo 
activities have been examined. A summary of studies carried out using non-liposomes 
nanoformulations of ZOL for cancer therapeutics are described in Table 1. Studies using 
liposome formulations of ZOL are described in more detail below. 
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A stealth liposome formulation of ZOL (LipoZOL) was shown to enhance delivery of ZOL to 
extra-skeletal sites through the EPR effect [41]. LipoZOL (Formulation 1) composed of Egg 
PC, DSPE-PEG2000 and cholesterol was compared to free ZOL both in vitro and in vivo. In 
vitro, LipoZOL showed lower IC50 values compared to free ZOL for 15 of the 17 cancer cell 
lines tested. CD-1 athymic (nu/nu) mice bearing PC3 xenografts were treated with 10 or 20 
µg of ZOL intravenously in its free form or as LipoZOL-PEG three times a week for three 
weeks. These experiments revealed tumour reductions of 16% and 22% following treatment 
with 10 and 20 µg respectively of free ZOL compared to tumour inhibition of 58% and 68% 
when treated with 10 or 20 µg of ZOL administered as LipoZOL-PEG. [41]. 
 
A hybrid nanoparticle-liposome formulation (Formulation 2) has also been prepared 
consisting of a calcium phosphate core and an outer phospholipid bilayer (PLCaPZ NPs) 
[51]. Calcium phosphate nanoparticles (CaP NPs) were prepared to which ZOL could bind. 
These CaPZ NPs were then mixed with DOTAP/chol/DSPE-PEG2000 liposomes. The 
PLCaPZ NPs had lower IC50 values than free ZOL in all cancer cell lines tested including 
prostate, breast, head/neck, lung, pancreas and multiple myeloma cell lines [52]. In vivo 
studies were performed using immunosuppressed mice bearing PC-3 tumours. PLCaPZ NPs 
achieved a significant tumour weight inhibition of 45 % [53]. It is thought that when the 
hybrid nanoparticle is endocytosed into the cancer cell, the decreasing pH of the endosome 
causes the CaP to dissolve and the subsequent increase in osmotic pressure across the 
endosomal membrane leads to the disorganisation of the endosome, allowing the ZOL to be 
released into the cytosol [51]. The PLCaPZ nanoparticles were also compared to ZOL-
containing stealth liposomes (LipoZOL-PEG). The stealth liposomes had significantly lower 
encapsulation efficacy compared to the PLCaPZ NPs (5.6% vs. 66%). Both formulations 
achieved an inhibition in tumour weight; PLCaPZ NPs showed a 52% reduction of tumour 
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burden while LipoZOL-PEG caused a reduction of 28%. Tumour growth delay was also seen 
in the case of PLCaPZ NPs (12 days) and for LipoZOL-PEG (7 days) compared to the 
untreated group [52].  
 
ZOL containing liposomes have also been modified to obtain a targeted drug delivery system. 
Shmeeda et al. prepared ZOL formulations with or without 0.5 % molar ratio folate-PEG 
(3350)-DSPE.  In vitro toxicity of the formulations as well as free ZOL after 72 hours was 
evaluated on various cell lines. It was shown that both targeted and non-targeted formulations 
had little toxicity against low folate receptor (FR)-expressing normal human fibroblasts and 
J774 macrophages. However while the untargeted formulation had an IC50 value of more than 
200 μM for the high FR expressing KB cell line, the folate targeted version had an IC50 value 
of 0.4 μM. Similarly, a human ovarian cancer cell line IGROV-1 which naturally 
overexpresses FR had an IC50 of 0.1 µM which is significantly lower than the IC50 obtained 
from non-targeted L-ZOL (IC50=50µM) or free ZOL (IC50=35 µM). Drug uptake was 
examined using a radioactive zoledronic acid tracer (C14-ZOL) and shown to be 50 and 25 
times higher for targeted liposomes compared to the non-targeted liposomes and the free 
ZOL, respectively [54]. 
 
However, because the liposomal ZOL has a different biodistribution profile to free ZOL, an 
increase in systemic toxicity was seen during an in vivo studies in mice [55]. In contrast to the 
decrease in in vivo toxicity observed with the liposomal encapsulation of other cytotoxic 
drugs [56], the liposomal formulations of ZOL showed a large increase in systemic toxicity 
compared to the free drug. This toxicity was also observed when liposomal ZOL was used 
with γδ T cells, as previously mentioned [57]. C-14 ZOL and H3-Chol was used to track the 
ZOL and the liposomes in vivo [55].The liposomal formulations showed half-lives of 9-18 
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hours while free ZOL was almost totally cleared from the plasma within one hour.  KB or 
IGROV-1 tumour bearing mice were treated with free ZOL or a ZOL liposome formulation, 
with mice receiving 30 μg ZOL in each case. Mice injected with 30 µg of ZOL in the 
liposome formulations died 5-7 days after injection whereas only occasional deaths (10-20%) 
were observed with 100 µg of free ZOL. Higher levels of ZOL were found in the spleen, 
liver, lung and skin when the liposomal formulations were given. Splenomegaly, leukocytosis 
and thrombocytopenia were observed in the mice injected with ZOL liposome formulations. 
No overt signs of toxicity were seen when the mouse organs were histopathologically 
examined. Tumour cells, endothelial cells, tumour-associated macrophages and other tumour-
infiltrating cells were exposed to higher concentrations of drugs than if the free drug was 
given. It was found that a co-injection of a large amount of blank liposomes with the ZOL 
liposome formulations reduced the systemic toxicity and enabled higher doses of ZOL 
liposomes to be injected. This indicates that macrophage uptake was involved in the 
mechanism of systemic toxicity. Low drug:lipid ratios also lowered the toxicity of the ZOL 
liposomes [55]. Because of this, it is suggested that the systemic toxicity may be due to 
macrophage activation that leads to a cytokine storm [55]. This hypothesis is supported by 
previous in vivo work with free ZOL [58].  
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Table 1: Cancer therapy studies using non-liposomal ZOL nanoformulations 
Study Formulation Composition of 
formulation 
Experimental 
Parameters 
Cell Line Findings 
Benyettou et 
al, 2009 [59] 
γFe2O3@ZOL ZOL and γFe2O3 
nanocrystals 
Nanoparticles incubated 
with cells for 48 and 72 h 
at various concentrations 
with or without a 
magnetic field 
MDA-MB-231 75% proliferation decrease with 
magnetic field and 40% without 
at 100µmol L
-1
 
Agrati et al, 
2011[60] 
ZOL niosomes Tween 20-Chol-
DCP (dicetyl 
phosphate) with 
or without ε-PLL 
(L-lysine 
polymer) 
Niosomes were incubated 
with leukocytes and γδ T 
cell activation was 
monitored by analysing 
IFN-γ production. 
Human leukocytes 
and lympho-
monocytes from 
healthy donors 
29.7-48.3% of the γδ T cells were 
activated by the ZOL loaded 
noisome clusters 
Liu et al, 2012 
[61] 
Nanoscale 
Coordination 
polymer with ZOL 
CaCl2·2H2O was 
loaded with ZOL 
and surrounded 
by DOTAP/ 
DOPE (1:1 mol) 
liposomes 
Formulations were 
incubated with cell lines 
and cell apoptosis was 
measured by Annexin V-
FITC 
H460 cells and 
AsPC-1  
IC50 values of 1.0 ± 0.5 µM with 
H460 cells and 3.6 ± 2.3 µM for 
AsPC-1 cells 
Chen et al, 
2013 [62] 
Lipid coated 
calcium phosphate 
nanoparticles 
containing ZOL and 
double-stranded 
RNA (poly (I:C)) 
Calcium 
phosphate, poly 
(I:C), zoledronate, 
DOTAP and 
cholesterol 
Nanoparticles incubated 
with cells for 48 h and 
cytotoxicity assessed by 
MTT assay. Animal 
studies carried out in 
female C57BL/6 mice. 
Formulations given to 
result in 4.5µg ZOL per 
mouse  
Mouse melanoma 
cell line B16BL6 
Nanoparticles containing poly 
(I:C) and ZOL had a cell viability 
of 14.4% Nanoparticles 
containing poly (I:C) and ZOL 
resulted in significant tumour 
growth inhibition (p<0.05) 
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2.2 ALD nanoformulations  
ALD has been frequently used as a targeting moiety on nanoparticles for delivery of 
therapeutic agents to the bone [63-67]. However, it has also been encapsulated into 
nanoparticles for its anti-cancer and other pharmacological activities. ALD has also been co-
encapsulated with doxorubicin (DOX) into liposomes [68]. Liposomes encapsulating both 
drugs (PLAD) were shown to be superior to liposomes encapsulating DOX alone (PLD). 
PLAD was shown to be more cytotoxic than PLD in several cell lines tested in vitro. PLAD 
was also shown to be more effective than PLD at inhibiting tumour growth in 4T1 breast 
cancer and M109R lung cancer models in BALB/c mice in vivo. ALD has also been 
encapsulated in nanoformulations other than liposomes for use in anti-cancer therapy. These 
studies are summarised in Table 2. 
 
Liposomal ALD has also been studied for its ability to deplete macrophages. ALD liposomes 
have been shown to inhibit macrophages in vitro and deplete circulating monocytes in rabbits 
in vivo [69]. This anti-inflammatory activity of ALD liposomes has shown to be effective in 
the inhibition of restenosis (the recurrence of narrowing of an artery following corrective 
treatment, for example, by angioplasty or stent) in rabbits in vivo [69]. Negatively-charged 
ALD liposomes have been found to be more potent inhibitors of monocytes and macrophages 
than neutral ALD liposomes in vitro [70]. Liposomal ALD was also shown to cause cytokine 
activation of human blood ex vivo, with increased levels of IL-1β, TNF-α, IFN-γ, IL-5, IL-6, 
IL-8, IL-10 and IL-12p70. In vivo secretion of IL-1β was also observed but there was no 
complement activation seen [70]. The ability of ALD liposomes to deplete monocytes and 
macrophages has also been shown to inhibit restenosis and endometriosis in a rat model [71]. 
However, while both IP and IV administration of ALD liposomes were effective in restenosis 
inhibition, only IP injections were effective in the treatment of endometriosis. ALD 
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liposomes have also been shown to deplete monocytes and macrophages in non-human 
primate model of human disease in vivo [72]. At doses of 0.1 mg/kg, a more than 50 % 
decrease in levels of circulating monocytes and tissue-resident macrophages was observed. 
The treatment was also shown to be well tolerated with no adverse clinical side effects 
observed. A clinical trial to evaluate the use of ALD in the prevention of coronary artery 
restenosis is due to commence [73].  
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Table 2: Cancer therapy studies using non-liposomal ALD nanoformulations 
Study Formulation Composition of 
formulation 
Experimental 
Parameters 
Cell Line Findings 
Dolatabadi 
et al., 2014 
[74] 
Solid lipid 
nanoparticles 
Solid lipid 
Precirol
®
 ATO 5 or 
Compritol 888 ATO
®
 
with Tween 20 and 
Poloxamer 407 as 
surfactants 
Particles incubated with 
cells for 24 h prior to 
MTT assay 
A549 lung carcinoma 
cells 
ALD solid lipid nanoparticles 
did not have significant toxicity 
Zhan et al., 
2014 [75] 
Glucomannan 
conjugates 
Glucomannan 
polysaccharide 
conjugated to ALD 
Conjugates incubated 
with cells for 24 h prior to 
MTT assay. Cell cycle 
and cell apoptosis 
measured with flow 
cytometry 
S180 tumour bearing 
mice treated with 10 
mg/kg free or conjugated 
ALD 
Mouse macrophage cell 
line Raw 264.7, mouse 
sarcoma cells S180, 
HUVECs and human 
lung carcinoma A549   
Viability of cells reduced in 
vitro treated with free of 
conjugated ALD 
Conjugated ALD significantly 
inhibited increase in tumour 
size and eliminate tumour 
associated macrophages 
Zhu et al., 
2014 [76] 
Nanoparticles Zirconium based 
metal-organic 
frameworks of UiO-66 
conjugated with ALD 
UiO-66 and ALD 
nanoparticles incubated 
with cells for 24 and 48 h 
HepG2 liver carcinoma 
cells and MCF-7 breast 
cancer cells 
After 48 h incubation, the UiO-
66 and ALD nanoparticles led 
to higher cytotoxicity than free 
ALD 
Massey et 
al., 2016 
[77]  
Nanoparticles 
 
 
 
 
 
 
  
Alendronate was 
complexed with the 
cationic amphiphilic 
peptide RALA to 
spontaneously form 
nanoparticles 
Particles were incubated 
with cells for 6 h and cells 
were incubated with fresh 
media for 72 h prior to 
MTS assay. PC-3 tumour 
bearing BALB/c SCID 
treated with 10 µg free 
ALD or ALD in particles 
PC3 prostate cancer 
cells and MDA-MB-231 
breast cancer cells 
Complexation with RALA 
potentiated the cytotoxic effects 
of ALD in vitro. 
Significant growth delay of 
tumours and increase in mean 
survival time in vivo  
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3.Gamma Delta T cells 
3.1 Functions of gamma delta T cells  
 
N-BPs can be used in cancer immunotherapy due to their ability to activate gamma delta (γδ) 
T cells [4]. γδ T cells are a subset of human T lymphocytes. They develop in the thymus with 
αβ T cells but have a rearranged T cell receptor (TCR) consisting of a TCR-γ and a TCR-δ 
chain [78]. γδ T cells can also be grouped according to tissue location or by the variable 
segments of the γ and δ TCR chains. They represent 1-10% of all peripheral blood T cells 
[79] and can be found widely in the skin, intestines and reproductive tract where they can 
make up to 50 % of T cells [80]. They are also present in the liver, spleen and thymus [81]. 
There are three main Vδ chains (Vδ1, Vδ2 and Vδ3) and seven main Vγ chains (Vγ2, Vγ3, 
Vγ4, Vγ5, Vγ8, Vγ9 and Vγ11) [82]. In humans, peripheral blood γδ T cells express mainly 
the Vγ9Vδ2 T Cell Receptor (TCR) [83], while in peripheral organs Vδ1 and Vδ3 are the 
predominant variant present [81]. Peripheral blood γδ T cells can proliferate to make up to 
50% of total peripheral T lymphocytes when stimulated and that this expansion can last up to 
four months following some microbial infections [84, 85]. Due to the heterogeneity of their 
TCRs and the fact that they are not major histocompatibility complex (MHC) restricted, γδ T 
cells have a diverse range of roles in the immune system (Figure 3). They are implicated in 
the immune response to infectious diseases, autoimmune disease and tumour surveillance 
[80]. They are associated with the innate function of the immune system as they have a rapid 
cytokine response and mainly reside in mucosal tissues [86]. They share effector functions 
with alpha beta (αβ) T cells and natural killer (NK) cells [87, 88]. γδ T cells have also been 
shown to share some properties with antigen-presenting cells such as dendritic cells [89] and 
may have an immunoregulatory role [90].  
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Figure 3: Illustration of the role of γδ T cells in the immune system. γδ T cells have been 
shown to have a wide range of roles in the immune system through six main mechanisms; (1) 
γδ T cells can produce granzymes to directly lyse infected or stressed cells, (2) they secrete a 
range of cytokines and chemokines which regulate both immune and non-immune cells; (3) 
they assist B cells and promote the production of IgE, (4) they can present antigens to αβ T 
cells, (5) they can trigger dendritic cell maturation and (6) they produce growth factors to 
regulate stromal cell function (Adopted from Pierre Vantourout & Adrian Hayday, 2013 
[91]). 
 
When activated γδ T cells secrete perforin and granzymes (cytoplasmic granule toxins) as 
well as cytokines such as IFN-γ and tumour necrosis factor (TNF)-α. Fas ligand (FasL) and 
TNF-related apoptosis-inducing ligand (TRAIL) expression by γδ T cells is also up-regulated 
[92]. Some γδ T cells also express CD16 (the low affinity Fc receptor for IgG) which can 
bind to anti-tumour cell monoclonal antibodies, thereby promoting antibody-dependent 
cellular cytotoxicity [83]. They can also induce NK cell-mediated cytotoxicity through the 
CD137 pathway [93]. A subset of γδ T cells which have low or no CD27 surface expression 
produce IL-17 [94].  Some of the multiple functions of γδ T cells are displayed in Figure 4.  
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Figure 4: Multiple functions of γδ T cells. (1) Following T cell receptor (TCR)-dependent 
activation, γδ T cells release perforin and granzymes, as an early step of their cytotoxic 
activity. (2) CD16
+
 effector γδ T cells bind to the Fc region of monoclonal antibodies that 
target tumour cells, thereby exercising their antibody-dependent cellular cytotoxicity (ADCC) 
function. (3) γ interferon (INFγ) and tumour necrosis factor α (TNFα) secretion by γδ T cells 
indicate their implication in immune defence/response networks. (4) Upon TCR engagement, 
Fas ligand (Fas-L) and TNF-related apoptosis-inducing ligand (TRAIL) expression is up-
regulated in γδ T cells and as, a consequence, the Fas- or TRAIL-receptor (R) sensitive 
tumour cell killing by γδ T cells is enhanced. (5) Human γδ T cells can act as professional 
antigen-presenting cells because they can process and display antigens and can also provide 
co-stimulatory signals necessary for the induction of proliferation, differentiation and target 
cell killing. MHC, major histocompatibility complex. (Adopted from Braza et al, 2013 [95]). 
 
3.2 γδ T cell activators 
γδ T cells recognise a diverse range of antigens. While γδ T cells can  recognise antigens in a 
non-MHC dependant manner, MHC molecules have also been shown to be ligands for the γδ 
TCR [96] such as MHC class I polypeptide related sequence (MIC) A, MICB and UL16 
binding protein (ULBP) which activate γδ T cells [85, 97]. Soluble proteins such as the 
tetanus toxoid [98], bacterial proteins [99], viral proteins [100] and heat shock proteins (HSP) 
[101] can stimulate γδ T cells. It has also been shown that γδ T cells can recognise cell-
surface expressed proteins other than MHC molecules [102]. Human γδ T cells also recognise 
group 1 CD1 molecules that are mainly found on professional antigen presenting cells and 
present lipid antigens such as glycolipids and microbial lipids [103]. Additionally, γδ T cells 
have been shown to respond to peptides without requiring antigen presenting cells [104]. γδ T 
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cells have high levels of expression of the IL-2 receptor and this cytokine is necessary for 
their survival and proliferation [105]. 
 
γδ T cells that express the Vγ9Vδ2 TCR are activated by phosphorylated antigens in a MHC-
independent manner [95] without the need to process and present these antigens [106]. These 
antigens are usually natural metabolites known as natural phospho-antigens (PAgs), for 
example, isopentyl pyrophosphate (IPP). These PAgs are produced by many different 
microorganisms such as Escherichia coli, Mycobacterium tuberculosis and Plasmodium 
falciparum [107]. They are also overproduced in dysregulation of the mevalonate pathway in 
human cells, such as in the case of tumour cells [108]. When activated by the PAgs, γδ T 
cells activate innate immune cells and are also directly involved in the elimination of some 
pathogens or tumour cells [95]. Cell-to-cell contact has been shown to be necessary to 
achieve γδ T cell activation [109]. While the PAgs are recognised in a TCR-dependent 
manner, it is thought that the PAgs may induce the structural modification of the TCR [110]. 
The PAgs bind to the intracellular B30.2 domain of the butyrophilin 3A1 (BTN3A1) protein 
[111]. BTN3A1 is a member of the BTN3A family, also known as CD277 which have been 
shown to have immunoregulatory functions [112]. It is hypothesised that binding of a ligand 
to the B30.2 domain leads to a conformational change which then modulates the extracellular 
domains of BTN3A1. It is not known however whether BTN3A1 can directly activate the 
Vγ9Vδ2 TCR, or if other as yet unknown proteins may be recruited in order to do this [82]. 
RhoB has been shown to be a critical mediator in Vγ9Vδ2 activation [113]. 
 
Nitrogen containing bisphosphonates (N-BPs) are a class of drug that inhibit FPP synthase 
and lead to intracellular accumulation of PAgs such as IPP and triphosphoric acid I-adenosin-
5’-yl ester 3-(3-methylbut-3-enyl) ester (ApppI) [114] as shown in Figure 5. Conversely, 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
21 
 
statins reduce IPP accumulation by inhibiting 3-hydroxy-3-methylglutaryl-coenzyme A 
reductase (HMGCR) of the mevalonate pathway and therefore reducing γδ T cell activation 
[4]. N-BPs can also inhibit γδ T cell proliferation upon continuous exposure both in vivo and 
during ex vivo expansion due to blocking of isoprenoid metabolism in γδ T cells leading to 
decreased levels of farnesyl pyrophosphate and geranylgeranyl pyrophosphate. This results in 
decreased cell proliferation and survival. An alternative method of pulsing γδ T cells with N-
BPs results in good ex vivo expansions with reduced toxicity to the γδ T cells compared with 
continuous exposure [115]. Alkylamines also act as indirect stimulators of γδ T cells and 
cause the accumulation of PAgs by inhibition of FPP synthase in the same manner as N-BPs, 
however at much lower potency [116]. Mevalonate has also been shown to stimulate γδ T 
cells, though not to the same extent as the N-BPs. High exogenous mevalonate concentrations 
bypass normal regulation of 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) and 
increases the levels of downstream products such as IPP. This stimulation cannot be blocked 
by statins [115]. A mushroom extract, Polysaccharide K, has been shown to activate γδ T 
cells which may partly account for its in vivo anti-tumour and immunomodulatory effects 
[117].  
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Figure 5: Schematic representation of the mevalonate pathway and the effects of 
nitrogen-containing bisphosphonates. Nitrogen-containing bisphosphonates block the 
enzyme Farnesyl pyrophosphate synthase (FPP-synthase) preventing the prenylation of 
proteins and leading to the upstream accumulation of Appp1 and phosphoantigens such as 
Isopentenyl pyrophosphate (IPP). (Adapted from www.ufrgs.br) 
 
γδ T cells have also been shown to be activated by antibodies. Bispecific antibodies that bind 
CD3 or Vγ9 on γδ T cells and Her2/neu on pancreatic tumour cells have been developed 
[118]. Both the Her2/CD3 and Her2/Vγ9 antibodies resulted in enhanced γδ T cell 
cytotoxicity in vitro. Additionally, the Her2/Vγ9 antibody led to an enhanced release of 
perforin and granzymes. When pancreatic tumour bearing SCID/beige mice were treated with 
γδ T cells and the Her2/Vγ9 antibody, a reduction in tumour growth was observed. Vγ9Vδ2 T 
cells have also been specifically activated by nanobodies [119] which consists of a single 
immunoglobulin domain of the variable antigen binding region of non-conventional heavy 
chain only antibodies. 
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3.3 γδ T cells and cancer 
Vγ9Vδ2 T cells naturally recognise tumour cells through recognition of PAgs accumulated 
intracellularly [4] or interaction with cell surface proteins such as F1-ATPase [102]. A 
mutation in p53, present in more than 50 % of human cancers, has been shown to 
significantly upregulate the mevalonate pathway [120]. Other transformation induced 
changes of cell surface markers can enhance tumour immunogenicity and lead to recognition 
by Vγ9Vδ2 T cells [121]. The activation of Vγ9Vδ2 T cells by tumour cells is illustrated in 
Figure 6. They are thought to have an immunosurveillance role in detecting malignancies 
[106] and can also migrate into solid tumours as infiltrating lymphoctyes [122]. Infiltration of 
γδ T cells has been reported in many different tumour types including melanoma, ovary, 
colon, lung and prostate [123]. In melanoma patients, tumour infiltrating γδ T cells were 
significantly associated with lower mortality and relapse rates [124]. Additionally, patients 
who progressed to stage III or IV melanoma had a significantly decreased frequency of 
circulating Vγ9Vδ2 T cells. The presence of γδ T cells in tumour infiltrating lymphocytes 
(TIL) has also been shown to result in lower metastatic spread and a longer mean survival 
time [125, 126]. In vitro, Vγ9Vδ2 T cells that have been isolated from ascites of a colon 
cancer patient have been shown to be cytotoxic when cultured with colorectal cancer cell 
lines [126, 127]. However, the immunosuppressive microenvironment of the tumour can limit 
the effectiveness of the anti-tumour activity of γδ T cells [128].  
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Figure 6: Recognition of tumour cells by human γδ T cells. N-BPs block the mevalonate 
pathway in mammalian cells leading to increased intracellular IPP levels. IPP metabolites can 
also be converted into ApppI. Both IPP and ApppI can be presented at the cell surface and are 
recognised by the γδ TCR. γδ T cells also recognise MHC molecules such as MICA, MICB 
and ULBP as well as other cell-surface expressed proteins (Adapted from Kakimi et al, 2014 
[121]).  
 
Some cytotoxic compounds can trigger ‘immunogenic’ cell death including doxorubicin and 
oxaliplatin. These chemotherapeutic agents act on tumour cells in such a way that the host 
immune system recognises the dying tumour cell. A tumour-specific immune response occurs 
during cell death which results in an anti-tumour immune response leading to tumour 
eradication and prevention of relapse. This immunogenic cell death can prevent immune 
tolerance to tumour cells and is a crucial component of treatment efficacy [129]. γδ T cells 
can be recruited to a tumour after exposure to immunogenic chemotherapy and can contribute 
to the efficacy of the chemotherapy [130]. In vitro, pre-treatment with low concentrations of 
chemotherapeutic agents (doxorubicin, cisplatin, etoposide and vincristine) or ZOL have been 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
25 
 
shown to sensitise tumour cells to killing by γδ T cells with additive or synergistic effects. 
[131]. 
 
There are two main approaches to γδ T cell cancer immunotherapy; the in vivo expansion of 
γδ T cells by administration of compounds that activate them or the adoptive transfer of ex 
vivo activated γδ T cells. Many studies have been performed using one of these strategies as 
detailed below. 
 
 
3.4 In vivo expansion of γδ T cells 
Many clinical trials involving the in vivo activation of γδ T cells have been published in the 
literature for a wide variety of cancers as seen in Table 3. These trials are based on the co-
administration of N-BPs or other PAgs with IL-2 to patients, which have been shown to 
increase the number of circulating γδ T cells [132]. In vivo activation of γδ T cells does not 
occur in all patients however. For example, ten patients with Non-Hodgkin’s Lymphoma 
(NHL) of the B-cell type received 90 mg of pamidronate (PAM) followed by 0.25-3 million 
IU/m
2
 of IL-2 daily for six consecutive days. None of these patients showed a response to 
treatment and no activation or expansion of their γδ T cells was observed [133]. However, 
when nine patients were pre-selected on the basis of an in vitro γδ T cell response to 
PAM/IL-2 and the same treatment was given, 55% of patients showed a statistically 
significant increase in γδ T cell number in vivo and partial remission was seen in 33% of 
patients (indicated by >50% reduction for all measureable lymphoma manifestations and no 
new lesions for at least four weeks) [133]. The importance of IL-2 in the in vivo expansion of 
γδ T cells has been observed. A study conducted by Dieli et al attempted to induce activation 
of γδ T cells in vivo using ZOL alone or in combination with low-dose IL-2 in patients with 
metastatic hormone-refractory prostate cancer (HRPC). No expansion of γδ T cells were seen 
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in the group treated with ZOL alone while in the group treated with ZOL and IL-2, five out of 
nine patients showed an increase in γδ T cell population. In the group treated with ZOL alone 
one patient showed stable disease over 14 months and one showed partial remission (30% or 
more reduction or the longest diameter of all measureable lesions). In contrast, six out of the 
nine patients in the group treated with ZOL and IL-2 showed good clinical responses with 
four patients achieving stable disease for 14-16 months and two patients showing a partial 
remission [134]. 
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Table 3: Human studies of in vivo expansion of γδ T cells 
Study Carcinoma Dosing Regimen Effect on γδ T cells Clinical Outcomes 
Wilhelm et al. 2003 
[133] 
NHL of the B-type 90mg PAM once and 0.25-
3 million IU/m
2
 IL-2 for 8 
days 
Significant proliferation in 55% of 
patients 
33% partial response (more than 50% 
reduction in manifestation), 22% disease 
stabilisation (less than 50% reduction in 
manifestations). 
Dieli et al, 2007 [134] Metastatic hormone 
refractory prostate 
cancer 
ZOL with or without IL-2. 
(Dose and frequency varied 
amongst patients) 
Increase in γδ T cell response seen Disease stabilisation or partial remission 
† 
Bennouna et al, 2010 
[135] 
Solid tumours BrHPP and IL-2. (Dose and 
frequency varied amongst 
patients). 
Strong amplification of γδ T cell in 
39 of 45 patients 
43% of patients had stable disease  † 
 
Meraviglia et al, 2010 
[136] 
Metastatic breast 
cancer 
4mg ZOL and 1 x 10
6 
IU 
IL-2 every 21 days over a 
one year period. 
The majority of patients saw a 
decrease in the number of γδ T cells 
when compared to pre-treatment 
levels. 
10% of patients had a  partial response 
and 20% stable disease † 
Lang et al, 2011 [137] Metastatic renal 
cell carcinoma 
4mg ZOL weekly for three 
weeks with varying IL-2 
dosing regimens 
Decrease in γδ T cell response No significant clinical effect seen † 
† Based on RECIST (Response Evaluation Criteria in Solid Tumour) criteria [138]. 
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3.5 Ex vivo expansion of γδ T cells 
γδ T cells that have been expanded ex vivo and are subsequently administered to cancer 
patients have also shown promising anti-tumour activity as summarised in Table 4. In these 
studies, γδ T cells are isolated from a patient and expanded ex vivo, typically in the presence 
of IL-2 and ZOL, for a period of time before being infused back into the patient [139]. 
Advanced renal cell carcinoma patients’ γδ T cells were expanded from PBMC over a two 
week period with IL-2 and the phosphoantigen, 2-methyl-3-butenyl-1-pyrophosphate 
(2M3B1-PP) before being re-infused to the patient. Three of the seven patients showed 
slower tumour growth [140]. γδ T cells have also been isolated from the tumour infiltration 
lymphocytes (TIL) of 15 non-small cell lung cancer patients and were expanded ex vivo for 
two weeks in the presence of ZOL and IL-2 before re-infusion. Six patients experienced brief 
disease stabilisation and there was an increase in mean progression free survival overall 
survival [141].  
 
Immunomonitoring whereby γδ T cells were labelled with indium 111 (In111) and tracked in 
patients have shown that cells are trafficked mainly to the lungs where they remain for 4-7 
hours before migrating to the liver and spleen in all patients [142] with only a minority of the 
γδ T cells reaching metastatic tumour sites. The γδ T cells were seen at tumour sites 1 hour 
after injection with maximum levels at 4 hours. Despite the small percentage of γδ T cells 
reaching tumour sites, several of the patients exhibited disease stabilisation or partial 
response; with one patient having a complete response. The number of γδ T cells that can 
reach the tumour site may limit the clinical efficacy of this treatment [132].  
 
A limitation to the use of autologous γδ T cells is the frequent impaired function of γδ T cells 
in cancer patients. The reason for this γδ T cells anergy has not been fully elucidated but 
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regulatory T cells have been shown to inhibit phosphoantigen-induced proliferation of γδ T 
cells [143]. This has also been observed in certain chronic infectious diseases such as HIV 
and tuberculosis [144]. As γδ T cells do not cause graft-versus-host disease (GVHD), the 
allogeneic transfer of γδ T cells is a viable option for immunotherapy [145]. Patients with 
advanced haematological malignancies received γδ T cells from half-matched family donors 
in addition to ZOL and IL-2 [146]. Three out of four patients treated achieved a complete 
remission with no signs of GVHD observed. 
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Table 4: Human studies of ex vivo expansion of γδ T cells 
Study Carcinoma Dosing Regimen Effect on γδ T cells Clinical Outcomes  
Kobayashi et al, 2007 
[140] 
Advanced renal cell 
carcinoma 
Autologous γδ T cells and 0.7 
million IU IL-2 per patient 
weekly 6-12 times 
Significant in vivo expansion 
and production of IFN-
gamma 
42% of patients had slower 
tumour growth † 
Bennouna et al, 2008 
[135] 
Metastatic renal cell 
carcinoma 
γδ T cells (Innate Pharma) given 
every 21 days for three cycles 
with 2 x 10
6
 IU/m
2
/day IL-2 for 
7 days after the 2
nd
 and 3
rd
 γδ T 
cell infusions 
γδ T cells increased 
substantially after the 2
nd
 and 
3
rd
 infusions 
60% of patients showed 
stabilised disease ‡ 
Abe et al, 2009 [147] Multiple myeloma Autologous γδ T cells given 
every 2 weeks for 4 cycles 
γδ T cells percentage in the 
PBMC increased 
substantially  
No significant clinical 
response seen. 
Nakajima et al, 2010 
[148] 
Non-small cell lung 
cancer  
Autologous γδ T cells given 
every 2 weeks for 3-12 cycles 
γδ T cells were shown to 
survive more than two weeks 
in vivo after infusion 
No complete response or 
stabilisation observed. Stable 
or improved ‘functional 
assessment of cancer-therapy-
biologic response modifier 
scores’ ‡ 
Kobayashi et al, 2011 
[149] 
Lung metastasis 
from renal cell 
carcinoma (one 
patient) 
4mg ZOL, 1.4 million IU IL-2 
and 0.3-3.5 x 10
9
 autologous γδ 
T cells monthly for 6 months 
Significant in vivo γδ T cell 
proliferation and IFN-
gamma production was seen. 
Complete remission of 
patient, currently ongoing two 
years after study with no 
further treatment ‡ 
Noguchi et al, 2011 
[150] 
Solid tumours Autologous γδ T cells given 3-6 
times 
All but three patients showed 
amplification of γδ T cells 
>10
8 
6 out of 25 patients 
experienced disease 
stabilisation ‡ 
Nicol et al, 2011 
[142] 
Advanced stage 
with various solid 
tumours 
Autologous γδ T cells given 6-8 
times 
Radiolabelled γδ T cells 
were tracked to metastatic 
tumour sites 
3 out of 18 patients had 
stabilised disease, 2 patients 
had partial response and 1 
patient had a complete 
response ‡ 
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Sakamoto et al, 2011 
[141] 
Recurrent or 
advanced non-small 
cell lung cancer 
Autologous γδ T cells given 
every 2 weeks for 6 cycles 
The number of peripheral γδ 
T cells increased after 
repeated infusions. 
50% of patients had stabilised 
disease ‡ 
Takamichi et al, 2013 
[151] 
Colorectal cancer Autologous γδ T cells (1.2 ± 0.6 
× 10
6
/kg) given weekly for 8 
weeks 
The number of peripheral γδ 
T cells increased after 
repeated infusions and were 
functionally active 
Not reported 
Wilhelm et al, 2014 
[146] 
Advanced 
haematological 
malignancies 
2.17 × 10
6
/kg (range 0.9-3.48) 
allogeneic γδ T cells, 4 mg ZOL 
and 1.0x10
6
 IU/m
2
 IL-2  
Mean 68 fold in vivo 
expansion of γδ T cells 
3 out of 4 patients had 
complete remission ‡ 
† Based on estimation of prolonged tumour doubling time by CT 
‡ Based on RECIST (Response Evaluation Criteria in Solid Tumour) criteria [138].
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3.6 Safety and efficacy of γδ T cell therapy 
γδ T cell therapy has been shown to be both feasible and safe [132]. In general, this 
immunotherapy has been well tolerated by patients. Mild adverse reactions such as flu-like 
symptoms, gastrointestinal disorders, hypotension and tachycardia have been reported. [135]. 
Some of these side effects are due to the ZOL and IL-2 often injected with the γδ T cells 
[134]. However, there are remaining issues and limitations to its use in cancer therapy. Some 
patients are hyporesponsive, whereby their γδ T cells fail to expand as expected, and 
activation-induced γδ T cell anergy (lack of γδ T cell activation or expansion) has been 
reported in many studies [132]. The use of allogeneic γδ T cells may overcome this 
limitation, however. 
 
The ability of γδ T cells to infiltrate tumours may pose a problem and the efficacy of γδ T 
cells may be limited by how successfully they can infiltrate established tumours [152]. 
Immunoescape whereby the cancer cells avoid immune system ‘checkpoints’ and 
immunoevasion where cancer cells fail to be detected by the immune system or secrete 
immunosuppressive molecules may also pose problems [132]. Tumours can produce 
inhibitory factors which can interfere with the proliferation and function of γδ T cells [152]. 
These include transforming growth factor (TGF)-β [153], prostaglandin-E2 [154], adenosine 
[155], soluble NKG2D ligands (such as MICA/B) [156], galectin-3 [157], HLA-G [158] and 
indoleamine 2,3 dioxygenase (IDO) [159]. There are also several types of suppressive cells in 
the tumour microenvironment which can inhibit the proliferation and cytotoxic effect of γδ T 
cells such as regulatory T cells [143], myeloid-derived suppressor cells [140] and 
mesenchymal stem cells [154].  
 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
33 
 
Genotyping patients for elevated levels of these inhibitory factors and suppressor cells prior 
to the use of γδ T cell therapy may be helpful in identifying which patients can benefit most 
from this treatment. Concomitant use of therapies that can overcome immunoescape may also 
be useful. These include the use of chemotherapeutic drugs that induce immunogenic cell 
death [129] or  non-specific immune stimulation by cytokines such as IL-2 and IFN-α, 
monoclonal antibodies and other biomolecules such as the anti-CD5 monoclonal antibody or 
the IL-2-diphtheria toxin conjugate [132]. Novel regimens that combine these drugs with 
PAgs or with γδ T cells are currently under investigation [132].  
 
3.7 γδ T cell therapy studies carried out in mice 
Murine studies have been undertaken to evaluate the effect of N-BPs as sensitising agents for 
γδ T cell immunotherapy. As mice do not have the Vγ9Vδ2 subset of T cells that are 
activated by N-BPs and other PAgs, human Vγ9Vδ2 T cells must be used in murine studies. 
In all studies described below and summarised in Table 5, the term γδ T cells refers to cells 
that have been isolated from human blood samples. In murine models, repeated inoculation 
with γδ T cells that have been isolated and expanded from human blood has been shown to 
delay or stop tumour progression in a wide range of cancer types including melanoma, 
prostate, lung, bladder and breast cancers [160-164]. Several different N-BPs have been used 
as a pre-treatment prior to the injection of γδ T cells in order to enhance the therapeutic 
efficacy of the γδ T cell treatments, with ZOL being the most common N-BP used.  
 
It was investigated whether pre-treating mice with ZOL 16 hours prior to injecting γδ T cells 
would improve survival time of nude/nude athymic mice with SH-SY-5Y neuroblastoma 
cells adrenal gland tumours [165]. Mice were injected i.v. with 5 × 106 γδ T cells, ZOL (150 
μg/Kg), or both, weekly, for 4 weeks. A statistically significant improvement of survival was 
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observed in mice receiving γδ T cells after ZOL pretreatment, in comparison with untreated 
mice or. In contrast, survival of mice treated with γδ T cells or ZOL alone was not 
significantly different from that of the control group. Infiltration of γδ T cells was 
significantly higher in tumours from mice receiving the combined treatment than when 
injected with γδ T cells alone. Additionally, IFN-γ production was clearly seen in tumours 
from mice receiving the combined treatment, whereas it was barely detectable in the tumours 
from mice receiving γδ T cells alone. SBC-5-Luc tumour-bearing BALB/c nu/nu mice treated 
with 80 mg/kg ZOL 12 h prior to 1 x 10
7
 γδ T cells showed similar results [166]. Tumour 
growth in mice treated with both ZOL and γδ T cells, but not with ZOL or γδ T cells, was 
significantly lower than tumour growth in untreated mice. γδ T cell and ZOL combinatory 
treatment has also been shown to result in prolonged survival in a murine orthotopic bladder 
model [162] compared to mice treated with γδ T cells or ZOL alone.  
 
ALD has also been shown to be an effective sensitiser for γδ T cell immunotherapy [167]. 
SCID beige mice inoculated i.p. with the melanoma cell line MeWO or the pancreatic cell 
line PancTu1 were concomitantly treated i.p. with human rIL-2 (300 ng), ALD (10 μg) and 
varying doses of γδ T cells. Increased mean survival of mice was observed. PAM (50 μg/kg 
i.v.) has been used 24 h prior to γδ T cells (1 × 106 i.v.) in PC3 tumour-bearing NSG mice 
[168]. When administered alone, PAM or γδ T cells had no detectable effect on PC3 tumour 
growth when compared with untreated controls. However, the growth of PC3 tumours was 
significantly decreased in mice receiving both PAM injection and γδ T cells when compared 
with other conditions. Immunohistochemical analysis showed the presence of infiltrating γδ T 
cells only within tumours of NSG mice that received both PAM and γδ T cells. When both 
PAM and γδ T cells injections were repeated weekly for four cycles, a strong and long-term 
control of PC3 tumour growth was achieved. Risedronate (RIS) has been used to stimulate 
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the γδ T cell expansion from human PBMCs implanted intraperitoneally in NOD/SCID mice 
[169]. Dose dependant stimulation, in the presence of IL-2, up to 50% of human T 
lymphocytes, was observed versus less than 10% for IL-2 alone. Additionally, a 46% 
reduction of the volume of T47D tumours was seen in mice treated with PBMC, IL-2 and 
RIS, when compared with placebo. Similar results were observed when using ZOL in a 
previous study by the same group [170].  
 
It was attempted to improve the therapeutic efficacy further by encapsulating ZOL in a 
liposome formulation [57]. However, after observing toxicity when liposomal ZOL was used, 
therapy studies were unable to be performed using this bisphosphonate. Further experiments 
were performed using the alternative bisphosphate, alendronic acid (ALD) in intraperitoneal 
(i.p) models of the ovarian cancer cell lines SKOV-3-luc and IGROV-1-luc in SCID/Beige 
mice. Mice were injected i.p. with two doses of free or liposomal ALD (30 μg and 100 μg), 
48 and 24 h prior to i.p. injection of 2 x 10
7
 γδ T cells. Free and liposomal ALD were shown 
to be equally effective and significant tumour regression was seen in these treatment groups 
(p < 0.001). However, when the free or liposomal ALD was delivered by i.v. injection (150 
μg) followed by three i.p. doses of 1 x 107 γδ T cells (24, 72 and 120 hours later), liposomal 
but not free ALD showed significant tumour regression. A study from our group [171], 
demonstrated significant inhibition of tumour growth in NSG mice with experimental lung 
metastatic cancer p < 0.05 after intravenous treatment of both L-ALD (0.5 μmol ALD/mouse) 
and γδ T cells (5 x 106 cells/mouse). Treatments with L-ALD or γδ T cells alone did not 
result in a significant delay in tumour growth. 
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Table 5: γδ T cell and N-BP studies in mice 
Name of 
Study 
Type of N-
BP 
Mouse 
Strain 
Tumour No. of γδ T 
cells 
Treatment Protocol Outcomes of Study 
Kabelitz et 
al (2004) 
[167] 
ALD (10 μg) SCID beige MeWO or 
PancTu1 (i.p.) 
Varied Treated i.p. with rIL-
2 (300 ng) and 10 μg 
ALD every 4 days 
and variable doses of 
γδ T cells i.p. on day 
0, 4, 10, 20 and 30  
Mean survival of mice increased from 
28.5 to 87.3 days (p < 0.0001) in mice 
inoculated with MeWo and from 23.0 to 
48.4 days (p < 0.0001) in the case of 
PancTu1. 
 
Sato et al 
(2005) 
[166] 
ZOL (80 
mg/kg) 12 h 
prior to γδ T 
cells 
BALB/c 
nu/nu. 10
7
  
SBC-5-Luc (sc) 1 x 10
7
 γδ T 
cells (i.v.)
 
Treated weekly for 3 
weeks 
Significant reduction in tumour growth 
(p < 0.05) 
Yuasa et al 
(2009) 
[162] 
ZOL (100 μl 
of 5 μM) 
Balb/c 
SCID,  
UM-UC-3Luc 
cells 
(intravesically 
administered into 
bladder cavity) 
1 x 10
7 γδ T 
cells 
(intravesically 
administered 
into bladder 
cavity)
 
Treatments were 
administered for 3 
hours on five 
sequential days. 
Photon emissions were significantly 
lower than the non-treatment groups 
and prolonged duration of survival with 
treatment (p < 0.001)  
Benzaid et 
al (2012) 
[169] 
RIS (150 
μg/kg) 
NOD/SCID T47D or B02 
cells (s.c) 
3.5 × 10
7
 
human PBMCs 
(i.p.) 
Every second day for 
14 days  
46% reduction of the volume of T47D 
tumours (p < 0.05)  
Santolaria 
et al 
(2013) 
[168] 
PAM (50 
μg/kg i.v.) 
24 hours 
prior to γδ T 
cells 
NSG PC3 (s.c.) 1 × 10
6
 γδ T 
cells i.v. 
Once off treatment 
or weekly for four 
weeks  
Significantly decreased tumour growth 
after once off treatment (10 mm versus 
20 mm in average diameter at week 5; p 
< 0.0005) and a strong and long-term 
control of tumour growth (p < 0.0005) 
after four treatments. 
 
Di Carlo et 
al (2013) 
ZOL (150 
μg/Kg) 16 
Nude/nude 
athymic 
SH-SY-5Y 
neuroblastoma 
 5× 106 γδ T 
cells (i.v.) 
From day 3 treated 
weekly for 4 weeks 
Significant improvement of survival (p 
= 0.024; 42 vs. 48 days for untreated 
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[165] hours prior 
to injection 
of γδ T cells 
mice cells (injected 
into adrenal 
gland).  
and treated mice, respectively). 
Parente-
Pereira et 
al (2014) 
[57] 
ALD or L-
ALD (30 μg 
and 100 μg 
i.p and  150 
μg i.v.) 
SCID/Beige  SKOV-3-luc and 
IGROV-1-luc 
(injected i.p). 
2 x 10
7
 γδ T 
cells (i.p.) 
Treated with ALD or 
L-ALD i.p., 48 and 
24 hours prior to γδ 
T cells. Or one dose 
of ALD or L-ALD 
i.v, followed by 
three i.p. doses of 1 
x 10
7
 γδ T cells, 24, 
72 and 120 hours 
later.  
Free and liposomal ALD were shown to 
be equally effective at reducing tumour 
growth (p < 0.001) when delivered i.p. 
whereas by i.v. injection liposomal but 
not free ALD showed significant 
tumour regression (p < 0.001). 
Hodgins et 
al (2016) 
[171] 
L-ALD (0.5 
μmol ALD/ 
mouse) i.v. 
NSG A375Pβ6 
(injected i.v.) 
 5× 106 γδ T 
cells (i.v.) 
Treated with L-ALD 
24 h prior to γδ T 
cells. once weekly 
for 3 weeks  
Only the group treated with both L-
ALD and γδ T cells showed significant 
inhibition of tumour growth (p < 0.05). 
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3.8 In vivo toxicity of liposomal N-BPs 
As mentioned above, death of mice injected with L-ZOL (0.1 µmol ZOL), without warning 
sign, has been reported to occur 5-7 days after injection BALB/c and outbred Sabra mice 
[54]. NSG mice were also found dead 5 days post i.v. injection of L-ZOL (0.1µmol ZOL) 
with no signs of physical abnormalities. However, NSG mice injected with mice injected with 
multiple doses of 0.5 µmol L-ALD showed 100% survival [171]. It has been suggested that 
the systemic toxicity of L-ZOL in mice is haematologically related and changes in the 
haematological profiles of mice injected with L-ZOL has previously been reported [54]. L-
ZOL and L-ALD caused leucocytosis, neutrophilia and lymphocytopenia [171]. White blood 
cells count and % neutrophils increased from 0.77 ± 0.15 x 10
9
/L and 66.2 ± 7.9 % in control 
mice to 3.22 ± 2.49 x 10
9
/L (p< 0.01) and 92.2 ± 4.3 % (p< 0.001), in the L-ZOL group, with 
similar results observed for mice injected with L-ALD. Additionally, spleens of mice injected 
with L-ZOL or L-ALD weighed significantly more (0.06 ± 0.02 g) than those of control mice 
(0.03 ± 0.004 g) (p < 0.01). This is thought to de due to the trafficking of damaged 
macrophages containing L-ZOL or L-ALD to the spleen. 
 
3.9 In vivo biodistribution of γδ T cells  
In order to better understand the effect of N-BPs on γδ T cells, several studies have looked at 
the in vivo biodistribution of γδ T cells. In one study from our group, human γδ T cells were 
labelled with [
111
In]tropolone, producing [
111
In]γδ T cells [172]. Whole body SPECT/CT 
imaging of [
111
In]γδ T cells, injected via the tail vein, in A375Pβ6 SC-tumour-bearing NSG 
mice, was performed to track the organ biodistribution of [
111
In]γδ T cells over time. The 
mice were imaged at multiple time points up to 24 h post-injection as shown in Figure 7. At 
early time points, [
111
In]γδ T cells were shown to accumulate in the lungs, and redistribute 
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overtime to the liver, spleen, and kidney. The biodistribution of [
111
In]tropolone was 
examined by SPECT/CT imaging at the same time points as a control. The pattern 
of biodistribution for [
111
In]tropolone was markedly different to that of the labelled γδ T cells, 
showing prolonged circulation and increased kidney excretion overtime. This suggests that 
the cells were successfully radiolabelled and the remained stable in vivo. Organ 
biodistribution of [
111
In]γδ T cells was assessed quantitatively by gamma counting, 
[
111
In]γδ T cells were cleared quickly from the blood with 6.1 – 8.8 % ID and 2.5 – 4.7 % ID 
present in blood at 30 min and 24 h, respectively. The liver and spleen showed high 
accumulation of [
111
In]γδ T cells with an uptake of 32.7 ± 1.3 and 47.2 ± 2.6 % ID/g, 
respectively. Low levels of 
111
In were present in the urine (0.11 ± 0.03) and faeces (0.43 ± 
0.29 % ID). Human γδ T cells labelled with [111In]oxine have also been imaged in vivo [142] 
in human patients and showed a similar pattern of biodistribution. Blood samples from these 
patients revealed that few cells were present in the bloodstream [142]. 
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Figure 7: In vivo whole body 3D SPECT/CT imaging of [
111
In]tropolone 
and [
111
In]Vγ9Vδ2 T cells in  subcutaneously (SC) implanted tumour-bearing 
SCID/Beige mice. γδ T cells were radiolabelled by incubation with [111In]tropolone. Any 
[
111In]tropolone not incorporated into the γδ T cells was removed by centrifugation.   
Tumour bearing NSG mice were intravenously injected with 5 x 10
6 
[
111In]γδ T cells or the 
equivalent amount of [
111
In]tropolone. The mice were imaged immediately and after 4 and 24 
hours. The γδ T cells go directly to the lung and then redistribute to the liver, spleen 
and kidneys over time. The pattern of biodistribution for [
111
In]tropolone was markedly 
different to that of the [
111In]γδ T cells, suggesting that the cells were stably labelled and have 
been successfully purified from any free  [
111
In]tropolone. 
 
 
 
 
 
 
4hr 24hr0-30 min
A375Pβ6
[1
1
1
In
]γ
δ
T
 c
el
ls
[1
1
1
In
]t
ro
p
o
lo
n
e
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
41 
 
L-ALD was used as a monotherapy and in combination with ex vivo-expanded Vγ9Vδ2 T 
cells in an experimental metastatic lung model with the αvβ6 positive A375Pβ6 melanoma 
cell line in NOD-SCID gamma (NSG) mice [173]. On day 6, all four groups had the same 
average tumour size (~1.3 x 10
6 
photons, as determined by bioluminescence imaging). L-
ALD or γδ T cells as monotherapies did not result in a significant reduction in tumour 
growth. Mice pre-treated with L-ALD 24 h prior to injection of γδ T cells showed a 
significant reduction in tumour growth, with tumour sizes of 7.53 x 10
7
 ± 2.02 x 10
7
 
compared to 1.42 x 10
9
 ± 6.38 x 10
8
 photons for naïve tumours on day 27 (Figure 8). IFN-γ 
serum levels were measured on day 27.  Mice pre-treated with L-ALD prior to γδ T cells had 
levels of 32.6 ± 19.3 and 12.3 ± 4.4 pg/ml (p < 0.05), respectively, compared to only 6.5 ± 
0.9 pg/ml in γδ T cells-only treated group, mirroring the significant reduction in tumour 
growth observed in these groups.  
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Figure 8: In vivo tumour therapy study. Experimental metastatic lung A375Pβ6 tumour 
bearing mice were treated intravenously on day 6 with L-ALD, (0.5 µmol ALD/mouse), 1 x 
10
7
 γδ T cells/mouse or were pre-treated with L-ALD 24 h prior to injection of γδ T cells. 
Three similar treatments were given intravenously at one week intervals, commencing on day 
6 post-tumour inoculation. Tumour progression was monitored by bioluminescence imaging. 
A significant reduction in tumour growth was observed for the L-ALD/ combinatory 
immunotherapy group compared to control mice or those treated with monotherapy of γδ T 
cells, L-ALD. Data was expressed as mean ± SEM (n=7). *p < 0.05, (one-way ANOVA vs. 
naïve) [173]. 
3.10 Active targeting of liposomal N-BPs 
Targeted liposomes have been formulated in order to try and increase the efficacy of the γδ T 
cell and L-ALD combinatory immunotherapy. The αvβ6 integrin specific peptide, 
A20FMDV2 was conjugated to the surface of L-ALD to produce t-L-ALD [173]. The ability 
of both L-ALD and t-L-ALD to sensitise cancer cell lines to destruction by Vγ9Vδ2 T cells 
was then tested by assessing cell viability and γδ T cell-derived IFN- γ production. The αvβ6 
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positive cell line A375Pβ6 was used in this assay. As shown in Figure 9, none of the 
treatments in isolation caused toxicity. However, when the cells were pre-treated with free or 
liposomal ALD, and were subsequently treated with γδ T cells, a significant decrease in cell 
viability was observed. t-L-ALD in combination with γδ T cells led to significantly lower cell 
viability than L-ALD at both 30 µM (p < 0.001) and 60 µM (p < 0.01) concentrations. To 
further confirm the increased sensitivity of αvβ6 positive cancer cells to γδ T cells when 
treated with t-L-ALD as compared to L-ALD, the IFN-γ release from the γδ T cells was 
quantified. Significantly higher amounts of IFN- γ were released when the γδ T cells were co-
cultured with cells pre-treated with t-L-ALD as compared to L-ALD (p < 0.001 and p < 0.001 
for 30 µM and 60 µM, respectively). This finding is in agreement with the results obtained by 
the MTT assay.  
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Figure 9: The ability of L-ALD and t-L-ALD to activate Vγ9Vδ2 T cells. (A) Cells were 
treated with ALD, L-ALD or t-L-ALD for 24 hours at 30 or 60 µM for 24 h. The treatments 
were then removed and replaced with 2 x 10
5
 γδ T cells for a further 24 h before a MTT assay 
was performed. t-L-ALD increased the sensitivity of A375Pβ6 cells to γδ T cells compared to 
L-ALD (grey bars). ALD, L-ALD or t-L-ALD did not cause cytotoxicity alone at the 
concentrations used (black bars).  (B) IFN-γ ELISA was performed on supernatant removed 
prior to the MTT assay. t-L-ALD led to higher release of IFN-γ from γδ T cells than L-ALD. 
Data was expressed as means ± SD (n=5). *p < 0.05, (one-way ANOVA L-ALD vs. t-L-
ALD) [173]. 
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Conclusions 
N-BPs have been shown to have anti-cancer activity both as a monotherapy and in 
combination with γδ T cells. Due to the biodistribution of N-BPs in vivo, encapsulation of N-
BPs in a nanoformulation is required for their use in the treatment of non-osseous tumours. 
Toxic side effects have been observed in vivo when ZOL and ALD were encapsulated into 
liposomes. L-ALD was shown to be better tolerated than L-ZOL. In vivo biodistribution and 
therapy studies performed by this group have shown promising results when L-ALD and γδ T 
cells are used in combination for the treatment of experimental metastatic lung tumours in 
immunocompromised mice. The use of αvβ6 ligand targeted L-ALD has shown to be more 
efficacious than non-targeted liposomes when used in combination with γδ T cells in vitro. 
Both murine and human studies have shown γδ T cell immunotherapy to be a well-tolerated 
and efficacious cancer therapy. Further work needs to be performed to understand the 
interaction of N-BPs with γδ T cells in vivo in order to fully realise their potential as a cancer 
treatment. While several different liposomal and non-liposomal N-BPs formulations have 
been used in combination with γδ T cells for different types of tumours and in different 
treatment protocols, optimisation of these are required to determine the most efficacious use 
of this combinatory immunotherapy.  Additionally, prior to liposomal N-BPs being used 
clinically, the increased toxicity of N-BPs when encapsulated into liposomes needs to be 
studied further to ensure that their use in human patients is safe.   
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
46 
 
References 
[1] A.P. Soares, R.F. do Espirito Santo, S.R. Line, M. Pinto, M. Santos Pde, M.B. Toralles, 
A.R. do Espirito Santo, Bisphosphonates: Pharmacokinetics, bioavailability, mechanisms of 
action, clinical applications in children, and effects on tooth development, Environmental 
toxicology and pharmacology, 42 (2016) 212-217. 
[2] R. Aft, M. Naughton, K. Trinkaus, M. Watson, L. Ylagan, M. Chavez-MacGregor, J. 
Zhai, S. Kuo, W. Shannon, K. Diemer, V. Herrmann, J. Dietz, A. Ali, M. Ellis, P. Weiss, T. 
Eberlein, C. Ma, P.M. Fracasso, I. Zoberi, M. Taylor, W. Gillanders, T. Pluard, J. Mortimer, 
K. Weilbaecher, Effect of zoledronic acid on disseminated tumour cells in women with 
locally advanced breast cancer: an open label, randomised, phase 2 trial, The Lancet 
Oncology, 11 (2010) 421-428. 
[3] E.F. Solomayer, G. Gebauer, P. Hirnle, W. Janni, H.J. Luck, S. Becker, J. Huober, B. 
Kramer, B. Wackwitz, D. Wallwiener, T. Fehm, Influence of zoledronic acid on disseminated 
tumor cells in primary breast cancer patients, Annals of oncology, 23 (2012) 2271-2277. 
[4] H.J. Gober, M. Kistowska, L. Angman, P. Jeno, L. Mori, G. De Libero, Human T cell 
receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells, The 
Journal of experimental medicine, 197 (2003) 163-168. 
[5] R.G. Russell, Bisphosphonates: the first 40 years, Bone, 49 (2011) 2-19. 
[6] V. Stresing, F. Daubine, I. Benzaid, H. Monkkonen, P. Clezardin, Bisphosphonates in 
cancer therapy, Cancer letters, 257 (2007) 16-35. 
[7] S.P. Luckman, D.E. Hughes, F.P. Coxon, R. Graham, G. Russell, M.J. Rogers, Nitrogen-
containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational 
prenylation of GTP-binding proteins, including Ras, Journal of bone and mineral research, 13 
(1998) 581-589. 
[8] J. Raikkonen, J.C. Crockett, M.J. Rogers, H. Monkkonen, S. Auriola, J. Monkkonen, 
Zoledronic acid induces formation of a pro-apoptotic ATP analogue and isopentenyl 
pyrophosphate in osteoclasts in vivo and in MCF-7 cells in vitro, British journal of 
pharmacology, 157 (2009) 427-435. 
[9] M. Caraglia, A.M. D'Alessandro, M. Marra, G. Giuberti, G. Vitale, C. Viscomi, A. Colao, 
S.D. Prete, P. Tagliaferri, P. Tassone, A. Budillon, S. Venuta, A. Abbruzzese, The farnesyl 
transferase inhibitor R115777 (Zarnestra) synergistically enhances growth inhibition and 
apoptosis induced on epidermoid cancer cells by Zoledronic acid (Zometa) and Pamidronate, 
Oncogene, 23 (2004) 6900-6913. 
[10] B. Sirohi, R. Powles, Multiple myeloma, Lancet, 363 (2004) 875-887. 
[11] R.G. Russell, Z. Xia, J.E. Dunford, U. Oppermann, A. Kwaasi, P.A. Hulley, K.L. 
Kavanagh, J.T. Triffitt, M.W. Lundy, R.J. Phipps, B.L. Barnett, F.P. Coxon, M.J. Rogers, 
N.B. Watts, F.H. Ebetino, Bisphosphonates: an update on mechanisms of action and how 
these relate to clinical efficacy, Annals of the New York Academy of Sciences, 1117 (2007) 
209-257. 
[12] J.R. Ross, Y. Saunders, P.M. Edmonds, S. Patel, D. Wonderling, C. Normand, K. 
Broadley, A systematic review of the role of bisphosphonates in metastatic disease, Health 
technology assessment, 8 (2004) 1-176. 
[13] J.R. Green, K. Muller, K.A. Jaeggi, Preclinical pharmacology of CGP 42'446, a new, 
potent, heterocyclic bisphosphonate compound, Journal of bone and mineral research, 9 
(1994) 745-751. 
[14] J.F. Lin, Y.C. Lin, Y.H. Lin, T.F. Tsai, K.Y. Chou, H.E. Chen, T.I. Hwang, Zoledronic 
acid induces autophagic cell death in human prostate cancer cells, The Journal of urology, 
185 (2011) 1490-1496. 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
47 
 
[15] S. Matsumoto, S. Kimura, H. Segawa, J. Kuroda, T. Yuasa, K. Sato, M. Nogawa, F. 
Tanaka, T. Maekawa, H. Wada, Efficacy of the third-generation bisphosphonate, zoledronic 
acid alone and combined with anti-cancer agents against small cell lung cancer cell lines, 
Lung cancer, 47 (2005) 31-39. 
[16] G.H. Green J, Yoneda T and Mundy G., Zoledronic acid potently inhibits tumour-
induced osteolysis in two models od breast cancer metastasis to bone., Annals of oncology, 
11 (suppl 4) (2000). 
[17] P.I. Croucher, R. De Hendrik, M.J. Perry, A. Hijzen, C.M. Shipman, J. Lippitt, J. Green, 
E. Van Marck, B. Van Camp, K. Vanderkerken, Zoledronic acid treatment of 5T2MM-
bearing mice inhibits the development of myeloma bone disease: evidence for decreased 
osteolysis, tumor burden and angiogenesis, and increased survival, Journal of bone and 
mineral research, 18 (2003) 482-492. 
[18] E. Giraudo, M. Inoue, D. Hanahan, An amino-bisphosphonate targets MMP-9-
expressing macrophages and angiogenesis to impair cervical carcinogenesis, The Journal of 
clinical investigation, 114 (2004) 623-633. 
[19] R.E. Coleman, H. Marshall, D. Cameron, D. Dodwell, R. Burkinshaw, M. Keane, M. 
Gil, S.J. Houston, R.J. Grieve, P.J. Barrett-Lee, D. Ritchie, J. Pugh, C. Gaunt, U. Rea, J. 
Peterson, C. Davies, V. Hiley, W. Gregory, R. Bell, A. Investigators, Breast-cancer adjuvant 
therapy with zoledronic acid, The New England journal of medicine, 365 (2011) 1396-1405. 
[20] G.J. Morgan, F.E. Davies, W.M. Gregory, K. Cocks, S.E. Bell, A.J. Szubert, N. Navarro-
Coy, M.T. Drayson, R.G. Owen, S. Feyler, A.J. Ashcroft, F. Ross, J. Byrne, H. Roddie, C. 
Rudin, G. Cook, G.H. Jackson, J.A. Child, G. National Cancer Research Institute 
Haematological Oncology Clinical Study, First-line treatment with zoledronic acid as 
compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised 
controlled trial, Lancet, 376 (2010) 1989-1999. 
[21] R. Mhaskar, J. Redzepovic, K. Wheatley, O.A. Clark, B. Miladinovic, A. Glasmacher, 
A. Kumar, B. Djulbegovic, Bisphosphonates in multiple myeloma: a network meta-analysis, 
The Cochrane database of systematic reviews, (2012) CD003188. 
[22] S. Ganguly, C.L. Divine, O.S. Aljitawi, S. Abhyankar, J.P. McGuirk, L. Graves, 
Prophylactic use of zoledronic acid to prevent early bone loss is safe and feasible in patients 
with acute myeloid leukemia undergoing allogeneic stem cell transplantation, Clinical 
transplantation, 26 (2012) 447-453. 
[23] J.R. Westin, M.A. Thompson, V.D. Cataldo, L.E. Fayad, N. Fowler, M.A. Fanale, S. 
Neelapu, F. Samaniego, J. Romaguera, J. Shah, P. McLaughlin, B. Pro, L.W. Kwak, P. 
Sanjorjo, W.A. Murphy, C. Jimenez, B. Toth, W. Dong, F.B. Hagemeister, Zoledronic acid 
for prevention of bone loss in patients receiving primary therapy for lymphomas: a 
prospective, randomized controlled phase III trial, Clinical Lymphoma Myeloma & 
Leukemia, 13 (2013) 99-105. 
[24] T. Okegawa, M. Higaki, T. Matsumoto, H. Kase, A. Murata, K. Noda, H. Noda, H. 
Asaoka, M. Oshi, J. Tomoishi, H. Uchida, E. Higashihara, K. Nutahara, G. Bone Metastasis 
Prostate Cancer, Zoledronic acid improves clinical outcomes in patients with bone metastatic 
hormone-naive prostate cancer in a multicenter clinical trial, Anticancer research, 34 (2014) 
4415-4420. 
[25] H.H. Van Acker, S. Anguille, Y. Willemen, E.L. Smits, V.F. Van Tendeloo, 
Bisphosphonates for cancer treatment: Mechanisms of action and lessons from clinical trials, 
Pharmacology & therapeutics, 158 (2016) 24-40. 
[26] K. Hashimoto, K. Morishige, K. Sawada, M. Tahara, S. Shimizu, S. Ogata, M. Sakata, 
K. Tasaka, T. Kimura, Alendronate suppresses tumor angiogenesis by inhibiting Rho 
activation of endothelial cells, Biochemica et Biophysica Research Communications, 354 
(2007) 478-484. 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
48 
 
[27] S.S. Virtanen, H.K. Vaananen, P.L. Harkonen, P.T. Lakkakorpi, Alendronate inhibits 
invasion of PC-3 prostate cancer cells by affecting the mevalonate pathway, Cancer research, 
62 (2002) 2708-2714. 
[28] A. Ilyas, Z. Hashim, N. Naeem, K. Haneef, S. Zarina, The effect of alendronate on 
proteome of hepatocellular carcinoma cell lines, International journal of proteomics, 2014 
(2014) 532953. 
[29] S. Muller, E. Migianu, M. Lecouvey, M. Kraemer, O. Oudar, Alendronate inhibits 
proliferation and invasion of human epidermoid carcinoma cells in vitro, Anticancer research, 
25 (2005) 2655-2660. 
[30] Y.Y. Cheng, L. Huang, K.M. Lee, K. Li, S.M. Kumta, Alendronate regulates cell 
invasion and MMP-2 secretion in human osteosarcoma cell lines, Pediatrric Blood and 
Cancer, 42 (2004) 410-415. 
[31] M. Rogers, S. Kalra, J. Moukharskaya, K. Chakraborty, M. Niyazi, K. Krishnan, J. 
Lightner, M. Brannon, W.L. Stone, V.E. Palau, Synergistic growth inhibition of PC3 prostate 
cancer cells with low-dose combinations of simvastatin and alendronate, Anticancer research, 
35 (2015) 1851-1859. 
[32] J.M. Tuomela, M.P. Valta, K. Vaananen, P.L. Harkonen, Alendronate decreases 
orthotopic PC-3 prostate tumor growth and metastasis to prostate-draining lymph nodes in 
nude mice, BMC cancer, 8 (2008) 81. 
[33] K. Hashimoto, K. Morishige, K. Sawada, M. Tahara, R. Kawagishi, Y. Ikebuchi, M. 
Sakata, K. Tasaka, Y. Murata, Alendronate inhibits intraperitoneal dissemination in in vivo 
ovarian cancer model, Cancer research, 65 (2005) 540-545. 
[34] J.M. Bruder, J.Z. Ma, N. Wing, J. Basler, D. Katselnik, Effects of alendronate on bone 
mineral density in men with prostate cancer treated with androgen deprivation therapy, 
Journal of clinical densitometry, 9 (2006) 431-437. 
[35] S.L. Greenspan, J.B. Nelson, D.L. Trump, N.M. Resnick, Effect of once-weekly oral 
alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a 
randomized trial, Annals of internal medicine, 146 (2007) 416-424. 
[36] M. Caraglia, M. Marra, S. Naviglio, G. Botti, R. Addeo, A. Abbruzzese, Zoledronic 
acid: an unending tale for an antiresorptive agent, Expert opinion on pharmacotherapy, 11 
(2010) 141-154. 
[37] S.C. Cremers, G. Pillai, S.E. Papapoulos, Pharmacokinetics/pharmacodynamics of 
bisphosphonates: use for optimisation of intermittent therapy for osteoporosis, Clinical 
pharmacokinetics, 44 (2005) 551-570. 
[38] B.J. Gertz, S.D. Holland, W.F. Kline, B.K. Matuszewski, A. Freeman, H. Quan, K.C. 
Lasseter, J.C. Mucklow, A.G. Porras, Studies of the oral bioavailability of alendronate, 
Clinical pharmacology and therapeutics, 58 (1995) 288-298. 
[39] J.H. Lin, Bisphosphonates: a review of their pharmacokinetic properties, Bone, 18 
(1996) 75-85. 
[40] S. Cremers, S. Papapoulos, Pharmacology of bisphosphonates, Bone, 49 (2011) 42-49. 
[41] M. Marra, G. Salzano, C. Leonetti, P. Tassone, M. Scarsella, S. Zappavigna, T. Calimeri, 
R. Franco, G. Liguori, G. Cigliana, R. Ascani, M.I. La Rotonda, A. Abbruzzese, P. 
Tagliaferri, M. Caraglia, G. De Rosa, Nanotechnologies to use bisphosphonates as potent 
anticancer agents: the effects of zoledronic acid encapsulated into liposomes, Nanomedicine : 
nanotechnology, biology, and medicine, 7 (2011) 955-964. 
[42] A.D. Bangham, M.M. Standish, J.C. Watkins, Diffusion of univalent ions across the 
lamellae of swollen phospholipids, Journal of molecular biology, 13 (1965) 238-252. 
[43] L. Sercombe, T. Veerati, F. Moheimani, S.Y. Wu, A.K. Sood, S. Hua, Advances and 
Challenges of Liposome Assisted Drug Delivery, Frontiers in pharmacology, 6 (2015) 286. 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
49 
 
[44] A. Madni, M. Sarfraz, M. Rehman, M. Ahmad, N. Akhtar, S. Ahmad, N. Tahir, S. Ijaz, 
R. Al-Kassas, R. Lobenberg, Liposomal drug delivery: a versatile platform for challenging 
clinical applications, Journal of pharmacy & pharmaceutical sciences, 17 (2014) 401-426. 
[45] G. Gregoriadis, E.J. Wills, C.P. Swain, A.S. Tavill, Drug-carrier potential of liposomes 
in cancer chemotherapy, Lancet, 1 (1974) 1313-1316. 
[46] P. Yingchoncharoen, D.S. Kalinowski, D.R. Richardson, Lipid-Based Drug Delivery 
Systems in Cancer Therapy: What Is Available and What Is Yet to Come, Pharmacological 
reviews, 68 (2016) 701-787. 
[47] D. Peer, J.M. Karp, S. Hong, O.C. Farokhzad, R. Margalit, R. Langer, Nanocarriers as 
an emerging platform for cancer therapy, Nature nanotechnology, 2 (2007) 751-760. 
[48] F. Yuan, M. Dellian, D. Fukumura, M. Leunig, D.A. Berk, V.P. Torchilin, R.K. Jain, 
Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff 
size, Cancer research, 55 (1995) 3752-3756. 
[49] R.K. Jain, Barriers to drug delivery in solid tumors, Scientific American, 271 (1994) 58-
65. 
[50] J. Lao, J. Madani, T. Puertolas, M. Alvarez, A. Hernandez, R. Pazo-Cid, A. Artal, A. 
Anton Torres, Liposomal Doxorubicin in the treatment of breast cancer patients: a review, 
Journal of drug delivery, 2013 (2013) 456409. 
[51] M. Hossann, T. Wang, M. Wiggenhorn, R. Schmidt, A. Zengerle, G. Winter, H. Eibl, M. 
Peller, M. Reiser, R.D. Issels, L.H. Lindner, Size of thermosensitive liposomes influences 
content release, Journal of controlled release : official journal of the Controlled Release 
Society, 147 (2010) 436-443. 
[52] M. Marra, G. Salzano, C. Leonetti, M. Porru, R. Franco, S. Zappavigna, G. Liguori, G. 
Botti, P. Chieffi, M. Lamberti, G. Vitale, A. Abbruzzese, M.I. La Rotonda, G. De Rosa, M. 
Caraglia, New self-assembly nanoparticles and stealth liposomes for the delivery of 
zoledronic acid: a comparative study, Biotechnology advances, 30 (2012) 302-309. 
[53] G. Salzano, M. Marra, M. Porru, S. Zappavigna, A. Abbruzzese, M.I. La Rotonda, C. 
Leonetti, M. Caraglia, G. De Rosa, Self-assembly nanoparticles for the delivery of 
bisphosphonates into tumors, International journal of pharmaceutics, 403 (2011) 292-297. 
[54] H. Shmeeda, Y. Amitay, J. Gorin, D. Tzemach, L. Mak, J. Ogorka, S. Kumar, J.A. 
Zhang, A. Gabizon, Delivery of zoledronic acid encapsulated in folate-targeted liposome 
results in potent in vitro cytotoxic activity on tumor cells, Journal of Controlled Release, 146 
(2010) 76-83. 
[55] H. Shmeeda, Y. Amitay, D. Tzemach, J. Gorin, A. Gabizon, Liposome encapsulation of 
zoledronic acid results in major changes in tissue distribution and increase in toxicity, Journal 
of Controlled Release, 167 (2013) 265-275. 
[56] D.W. Northfelt, F.J. Martin, P. Working, P.A. Volberding, J. Russell, M. Newman, M.A. 
Amantea, L.D. Kaplan, Doxorubicin encapsulated in liposomes containing surface-bound 
polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-
related Kaposi's sarcoma, Journal of clinical pharmacology, 36 (1996) 55-63. 
[57] A.C. Parente-Pereira, H. Shmeeda, L.M. Whilding, C.P. Zambirinis, J. Foster, S.J. van 
der Stegen, R. Beatson, T. Zabinski, N. Brewig, J.K. Sosabowski, S. Mather, S. Ghaem-
Maghami, A. Gabizon, J. Maher, Adoptive immunotherapy of epithelial ovarian cancer with 
Vgamma9Vdelta2 T cells, potentiated by liposomal alendronic acid, Journal of Immunology, 
193 (2014) 5557-5566. 
[58] G. Dicuonzo, B. Vincenzi, D. Santini, G. Avvisati, L. Rocci, F. Battistoni, M. Gavasci, 
D. Borzomati, R. Coppola, G. Tonini, Fever after zoledronic acid administration is due to 
increase in TNF-alpha and IL-6, Journal of interferon & cytokine research, 23 (2003) 649-
654. 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
50 
 
[59] F. Benyettou, Y. Lalatonne, O. Sainte-Catherine, M. Monteil, L. Motte, 
Superparamagnetic nanovector with anti-cancer properties: gamma Fe2O3@Zoledronate, 
International journal of pharmaceutics, 379 (2009) 324-327. 
[60] C. Agrati, C. Marianecci, S. Sennato, M. Carafa, V. Bordoni, E. Cimini, M. Tempestilli, 
L.P. Pucillo, F. Turchi, F. Martini, G. Borioni, F. Bordi, Multicompartment vectors as novel 
drug delivery systems: selective activation of Tgammadelta lymphocytes after zoledronic 
acid delivery, Nanomedicine : nanotechnology, biology, and medicine, 7 (2011) 153-161. 
[61] G. Liu, D. Zhang, Y. Jiao, D. Zheng, Y. Liu, C. Duan, L. Jia, Q. Zhang, H. Lou, 
Comparison of different methods for preparation of a stable riccardin D formulation via 
nano-technology, International journal of pharmaceutics, 422 (2012) 516-522. 
[62] L. Chen, Y. Ding, Y. Wang, X. Liu, R. Babu, W. Ravis, W. Yan, Codelivery of 
zoledronic acid and doublestranded RNA from core-shell nanoparticles, International journal 
of nanomedicine, 8 (2013) 137-145. 
[63] S.I. Thamake, S.L. Raut, Z. Gryczynski, A.P. Ranjan, J.K. Vishwanatha, Alendronate 
coated poly-lactic-co-glycolic acid (PLGA) nanoparticles for active targeting of metastatic 
breast cancer, Biomaterials, 33 (2012) 7164-7173. 
[64] W.L. Ye, Y.P. Zhao, H.Q. Li, R. Na, F. Li, Q.B. Mei, M.G. Zhao, S.Y. Zhou, 
Doxorubicin-poly (ethylene glycol)-alendronate self-assembled micelles for targeted therapy 
of bone metastatic cancer, Scientific reports, 5 (2015) 14614. 
[65] K. Miller, A. Eldar-Boock, D. Polyak, E. Segal, L. Benayoun, Y. Shaked, R. Satchi-
Fainaro, Antiangiogenic antitumor activity of HPMA copolymer-paclitaxel-alendronate 
conjugate on breast cancer bone metastasis mouse model, Molecular pharmaceutics, 8 (2011) 
1052-1062. 
[66] C. Clementi, K. Miller, A. Mero, R. Satchi-Fainaro, G. Pasut, Dendritic poly(ethylene 
glycol) bearing paclitaxel and alendronate for targeting bone neoplasms, Molecular 
pharmaceutics, 8 (2011) 1063-1072. 
[67] G. Wang, N.Z. Mostafa, V. Incani, C. Kucharski, H. Uludag, Bisphosphonate-decorated 
lipid nanoparticles designed as drug carriers for bone diseases, Journal of biomedical 
materials research., 100 (2012) 684-693. 
[68] H. Shmeeda, Y. Amitay, J. Gorin, D. Tzemach, L. Mak, S.T. Stern, Y. Barenholz, A. 
Gabizon, Coencapsulation of alendronate and doxorubicin in pegylated liposomes: a novel 
formulation for chemoimmunotherapy of cancer, Journal of drug targeting, (2016) 1-12. 
[69] H. Epstein, D. Gutman, E. Cohen-Sela, E. Haber, O. Elmalak, N. Koroukhov, H.D. 
Danenberg, G. Golomb, Preparation of alendronate liposomes for enhanced stability and 
bioactivity: in vitro and in vivo characterization, The AAPS journal, 10 (2008) 505-515. 
[70] H. Epstein-Barash, D. Gutman, E. Markovsky, G. Mishan-Eisenberg, N. Koroukhov, J. 
Szebeni, G. Golomb, Physicochemical parameters affecting liposomal bisphosphonates 
bioactivity for restenosis therapy: internalization, cell inhibition, activation of cytokines and 
complement, and mechanism of cell death, Journal of controlled release, 146 (2010) 182-195. 
[71] E. Haber, E. Afergan, H. Epstein, D. Gutman, N. Koroukhov, M. Ben-David, M. 
Schachter, G. Golomb, Route of administration-dependent anti-inflammatory effect of 
liposomal alendronate, Journal of controlled release, 148 (2010) 226-233. 
[72] B.J. Burwitz, J.S. Reed, K.B. Hammond, M.A. Ohme, S.L. Planer, A.W. Legasse, A.J. 
Ericsen, Y. Richter, G. Golomb, J.B. Sacha, Technical advance: liposomal alendronate 
depletes monocytes and macrophages in the nonhuman primate model of human disease, 
Journal of leukocyte biology, 96 (2014) 491-501. 
[73] ClinicalTrials.org, BLADE-PCI Trial (BLADE); PHASE IIB LIPOSOMAL 
ALENDRONATE STUDY (BLADE), in, https://clinicaltrials.gov/ct2/show/NCT02645799, 
2016. 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
51 
 
[74] J. Ezzati Nazhad Dolatabadi, H. Hamishehkar, M. Eskandani, H. Valizadeh, 
Formulation, characterization and cytotoxicity studies of alendronate sodium-loaded solid 
lipid nanoparticles, Colloids and surfaces. B, Biointerfaces, 117 (2014) 21-28. 
[75] X. Zhan, L. Jia, Y. Niu, H. Qi, X. Chen, Q. Zhang, J. Zhang, Y. Wang, L. Dong, C. 
Wang, Targeted depletion of tumour-associated macrophages by an alendronate-
glucomannan conjugate for cancer immunotherapy, Biomaterials, 35 (2014) 10046-10057. 
[76] X. Zhu, J. Gu, Y. Wang, B. Li, Y. Li, W. Zhao, J. Shi, Inherent anchorages in UiO-66 
nanoparticles for efficient capture of alendronate and its mediated release, Chem Commun 
(Camb), 50 (2014) 8779-8782. 
[77] A.S. Massey, S. Pentlavalli, R. Cunningham, C.M. McCrudden, E.M. McErlean, P. 
Redpath, A.A. Ali, S. Annett, J.W. McBride, J. McCaffrey, T. Robson, M.E. Migaud, H.O. 
McCarthy, Potentiating the Anticancer Properties of Bisphosphonates by Nanocomplexation 
with the Cationic Amphipathic Peptide, RALA, Molecular pharmaceutics, 13 (2016) 1217-
1228. 
[78] I. Prinz, B. Silva-Santos, D.J. Pennington, Functional development of gammadelta T 
cells, European journal of immunology, 43 (2013) 1988-1994. 
[79] M.S. Braza, A. Caraux, T. Rousset, S. Lafaye de Micheaux, H. Sicard, P. Squiban, V. 
Costes, B. Klein, J.F. Rossi, gammadelta T lymphocytes count is normal and expandable in 
peripheral blood of patients with follicular lymphoma, whereas it is decreased in tumor 
lymph nodes compared with inflammatory lymph nodes, Journal of Immunology, 184 (2010) 
134-140. 
[80] S.R. Carding, P.J. Egan, Gammadelta T cells: functional plasticity and heterogeneity, 
Nature Reviews Immunology, 2 (2002) 336-345. 
[81] M. Bonneville, R.L. O'Brien, W.K. Born, Gammadelta T cell effector functions: a blend 
of innate programming and acquired plasticity, Nature Reviews Immunology, 10 (2010) 467-
478. 
[82] E.J. Adams, S. Gu, A.M. Luoma, Human gamma delta T cells: Evolution and ligand 
recognition, Cellular immunology, 296 (2015) 31-40. 
[83] M.S. Braza, B. Klein, G. Fiol, J.F. Rossi, gammadelta T-cell killing of primary follicular 
lymphoma cells is dramatically potentiated by GA101, a type II glycoengineered anti-CD20 
monoclonal antibody, Haematologica, 96 (2011) 400-407. 
[84] A. Bertotto, R. Gerli, F. Spinozzi, C. Muscat, F. Scalise, G. Castellucci, M. Sposito, F. 
Candio, R. Vaccaro, Lymphocytes bearing the gamma delta T cell receptor in acute Brucella 
melitensis infection, European journal of immunology, 23 (1993) 1177-1180. 
[85] H. Das, V. Groh, C. Kuijl, M. Sugita, C.T. Morita, T. Spies, J.F. Bukowski, MICA 
engagement by human Vgamma2Vdelta2 T cells enhances their antigen-dependent effector 
function, Immunity, 15 (2001) 83-93. 
[86] P. Zarin, E.L. Chen, T.S. In, M.K. Anderson, J.C. Zuniga-Pflucker, Gamma delta T-cell 
differentiation and effector function programming, TCR signal strength, when and how 
much?, Cellular immunology, 296 (2015) 70-75. 
[87] M.C. Devilder, S. Maillet, I. Bouyge-Moreau, E. Donnadieu, M. Bonneville, E. Scotet, 
Potentiation of antigen-stimulated V gamma 9V delta 2 T cell cytokine production by 
immature dendritic cells (DC) and reciprocal effect on DC maturation, Journal of 
Immunology, 176 (2006) 1386-1393. 
[88] M.C. D'Ombrain, D.S. Hansen, K.M. Simpson, L. Schofield, gammadelta-T cells 
expressing NK receptors predominate over NK cells and conventional T cells in the innate 
IFN-gamma response to Plasmodium falciparum malaria, European journal of immunology, 
37 (2007) 1864-1873. 
[89] N. Himoudi, D.A. Morgenstern, M. Yan, B. Vernay, L. Saraiva, Y. Wu, C.J. Cohen, K. 
Gustafsson, J. Anderson, Human gammadelta T lymphocytes are licensed for professional 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
52 
 
antigen presentation by interaction with opsonized target cells, Journal of Immunology, 188 
(2012) 1708-1716. 
[90] Y. Konigshofer, Y.H. Chien, Gammadelta T cells - innate immune lymphocytes?, 
Current opinion in immunology, 18 (2006) 527-533. 
[91] P. Vantourout, A. Hayday, Six-of-the-best: unique contributions of gammadelta T cells 
to immunology, Nature reviews. Immunology, 13 (2013) 88-100. 
[92] M. D'Asaro, C. La Mendola, D. Di Liberto, V. Orlando, M. Todaro, M. Spina, G. 
Guggino, S. Meraviglia, N. Caccamo, A. Messina, A. Salerno, F. Di Raimondo, P. Vigneri, 
G. Stassi, J.J. Fournie, F. Dieli, V gamma 9V delta 2 T lymphocytes efficiently recognize and 
kill zoledronate-sensitized, imatinib-sensitive, and imatinib-resistant chronic myelogenous 
leukemia cells, Journal of Immunology, 184 (2010) 3260-3268. 
[93] A. Maniar, X. Zhang, W. Lin, B.R. Gastman, C.D. Pauza, S.E. Strome, A.I. Chapoval, 
Human gammadelta T lymphocytes induce robust NK cell-mediated antitumor cytotoxicity 
through CD137 engagement, Blood, 116 (2010) 1726-1733. 
[94] J.C. Ribot, A. deBarros, D.J. Pang, J.F. Neves, V. Peperzak, S.J. Roberts, M. Girardi, J. 
Borst, A.C. Hayday, D.J. Pennington, B. Silva-Santos, CD27 is a thymic determinant of the 
balance between interferon-gamma- and interleukin 17-producing gammadelta T cell subsets, 
Nature immunology, 10 (2009) 427-436. 
[95] M.S. Braza, B. Klein, Anti-tumour immunotherapy with Vgamma9Vdelta2 T 
lymphocytes: from the bench to the bedside, British journal of haematology, 160 (2013) 123-
132. 
[96] L.A. Matis, R. Cron, J.A. Bluestone, Major histocompatibility complex-linked 
specificity of gamma delta receptor-bearing T lymphocytes, Nature, 330 (1987) 262-264. 
[97] M.I. Hirsh, N. Hashiguchi, Y. Chen, L. Yip, W.G. Junger, Surface expression of HSP72 
by LPS-stimulated neutrophils facilitates gammadeltaT cell-mediated killing, European 
journal of immunology, 36 (2006) 712-721. 
[98] D. Kozbor, G. Trinchieri, D.S. Monos, M. Isobe, G. Russo, J.A. Haney, C. Zmijewski, 
C.M. Croce, Human TCR-gamma+/delta+, CD8+ T lymphocytes recognize tetanus toxoid in 
an MHC-restricted fashion, The Journal of experimental medicine, 169 (1989) 1847-1851. 
[99] C.J. Rust, F. Koning, Gamma delta T cell reactivity towards bacterial superantigens, 
Seminars in immunology, 5 (1993) 41-46. 
[100] R. Sciammas, R.M. Johnson, A.I. Sperling, W. Brady, P.S. Linsley, P.G. Spear, F.W. 
Fitch, J.A. Bluestone, Unique antigen recognition by a herpesvirus-specific TCR-gamma 
delta cell, Journal of Immunology, 152 (1994) 5392-5397. 
[101] R.L. O'Brien, M.P. Happ, A. Dallas, E. Palmer, R. Kubo, W.K. Born, Stimulation of a 
major subset of lymphocytes expressing T cell receptor gamma delta by an antigen derived 
from Mycobacterium tuberculosis, Cell, 57 (1989) 667-674. 
[102] E. Scotet, L.O. Martinez, E. Grant, R. Barbaras, P. Jeno, M. Guiraud, B. Monsarrat, X. 
Saulquin, S. Maillet, J.P. Esteve, F. Lopez, B. Perret, X. Collet, M. Bonneville, E. 
Champagne, Tumor recognition following Vgamma9Vdelta2 T cell receptor interactions with 
a surface F1-ATPase-related structure and apolipoprotein A-I, Immunity, 22 (2005) 71-80. 
[103] M. Sugita, M.B. Brenner, T lymphocyte recognition of human group 1 CD1 molecules: 
implications for innate and acquired immunity, Seminars in immunology, 12 (2000) 511-516. 
[104] W.K. Born, L. Zhang, M. Nakayama, N. Jin, J.L. Chain, Y. Huang, M.K. Aydintug, 
R.L. O'Brien, Peptide antigens for gamma/delta T cells, Cellular and molecular life sciences, 
68 (2011) 2335-2343. 
[105] J. Kjeldsen-Kragh, A.J. Quayle, B.S. Skalhegg, M. Sioud, O. Forre, Selective activation 
of resting human gamma delta T lymphocytes by interleukin-2, European journal of 
immunology, 23 (1993) 2092-2099. 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
53 
 
[106] Y.H. Chien, Y. Konigshofer, Antigen recognition by gammadelta T cells, 
Immunological reviews, 215 (2007) 46-58. 
[107] J. Feurle, E. Espinosa, S. Eckstein, F. Pont, V. Kunzmann, J.J. Fournie, M. Herderich, 
M. Wilhelm, Escherichia coli produces phosphoantigens activating human gamma delta T 
cells, The Journal of biological chemistry, 277 (2002) 148-154. 
[108] C.T. Morita, C. Jin, G. Sarikonda, H. Wang, Nonpeptide antigens, presentation 
mechanisms, and immunological memory of human Vgamma2Vdelta2 T cells: 
discriminating friend from foe through the recognition of prenyl pyrophosphate antigens, 
Immunological reviews, 215 (2007) 59-76. 
[109] F. Lang, M.A. Peyrat, P. Constant, F. Davodeau, J. David-Ameline, Y. Poquet, H. Vie, 
J.J. Fournie, M. Bonneville, Early activation of human V gamma 9V delta 2 T cell broad 
cytotoxicity and TNF production by nonpeptidic mycobacterial ligands, Journal of 
Immunology, 154 (1995) 5986-5994. 
[110] Y. Tanaka, S. Sano, E. Nieves, G. De Libero, D. Rosa, R.L. Modlin, M.B. Brenner, 
B.R. Bloom, C.T. Morita, Nonpeptide ligands for human gamma delta T cells, Proceedings of 
the National Academy of Sciences of the United States of America, 91 (1994) 8175-8179. 
[111] A. Sandstrom, C.M. Peigne, A. Leger, J.E. Crooks, F. Konczak, M.C. Gesnel, R. 
Breathnach, M. Bonneville, E. Scotet, E.J. Adams, The intracellular B30.2 domain of 
butyrophilin 3A1 binds phosphoantigens to mediate activation of human Vgamma9Vdelta2 T 
cells, Immunity, 40 (2014) 490-500. 
[112] L. Abeler-Dorner, M. Swamy, G. Williams, A.C. Hayday, A. Bas, Butyrophilins: an 
emerging family of immune regulators, Trends in immunology, 33 (2012) 34-41. 
[113] Z. Sebestyen, W. Scheper, A. Vyborova, S. Gu, Z. Rychnavska, M. Schiffler, A. 
Cleven, C. Cheneau, M. van Noorden, C.M. Peigne, D. Olive, R.J. Lebbink, R. Oostvogels, 
T. Mutis, G.J. Schuurhuis, E.J. Adams, E. Scotet, J. Kuball, RhoB Mediates Phosphoantigen 
Recognition by Vgamma9Vdelta2 T Cell Receptor, Cell reports, 15 (2016) 1973-1985. 
[114] D. Hannani, Y. Ma, T. Yamazaki, J. Dechanet-Merville, G. Kroemer, L. Zitvogel, 
Harnessing gammadelta T cells in anticancer immunotherapy, Trends in immunology, 33 
(2012) 199-206. 
[115] H. Wang, G. Sarikonda, K.J. Puan, Y. Tanaka, J. Feng, J.L. Giner, R. Cao, J. 
Monkkonen, E. Oldfield, C.T. Morita, Indirect stimulation of human Vgamma2Vdelta2 T 
cells through alterations in isoprenoid metabolism, Journal of Immunology, 187 (2011) 5099-
5113. 
[116] K. Thompson, J. Rojas-Navea, M.J. Rogers, Alkylamines cause Vgamma9Vdelta2 T-
cell activation and proliferation by inhibiting the mevalonate pathway, Blood, 107 (2006) 
651-654. 
[117] C. Inatsuka, Y. Yang, E. Gad, L. Rastetter, M.L. Disis, H. Lu, Gamma delta T cells are 
activated by polysaccharide K (PSK) and contribute to the anti-tumor effect of PSK, Cancer 
immunology, immunotherapy, 62 (2013) 1335-1345. 
[118] H.H. Oberg, M. Peipp, C. Kellner, S. Sebens, S. Krause, D. Petrick, S. Adam-Klages, 
C. Rocken, T. Becker, I. Vogel, D. Weisner, S. Freitag-Wolf, M. Gramatzki, D. Kabelitz, D. 
Wesch, Novel bispecific antibodies increase gammadelta T-cell cytotoxicity against 
pancreatic cancer cells, Cancer research, 74 (2014) 1349-1360. 
[119] R.C. de Bruin, S.M. Lougheed, L. van der Kruk, A.G. Stam, E. Hooijberg, R.C. 
Roovers, P.M. van Bergen En Henegouwen, H.M. Verheul, T.D. de Gruijl, H.J. van der Vliet, 
Highly specific and potently activating Vgamma9Vdelta2-T cell specific nanobodies for 
diagnostic and therapeutic applications, Clinical immunology, 169 (2016) 128-138. 
[120] W.A. Freed-Pastor, H. Mizuno, X. Zhao, A. Langerod, S.H. Moon, R. Rodriguez-
Barrueco, A. Barsotti, A. Chicas, W. Li, A. Polotskaia, M.J. Bissell, T.F. Osborne, B. Tian, 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
54 
 
S.W. Lowe, J.M. Silva, A.L. Borresen-Dale, A.J. Levine, J. Bargonetti, C. Prives, Mutant p53 
disrupts mammary tissue architecture via the mevalonate pathway, Cell, 148 (2012) 244-258. 
[121] K. Kakimi, H. Matsushita, T. Murakawa, J. Nakajima, gammadelta T cell therapy for 
the treatment of non-small cell lung cancer, Translational lung cancer research, 3 (2014) 23-
33. 
[122] E. Viey, C. Lucas, F. Romagne, B. Escudier, S. Chouaib, A. Caignard, Chemokine 
receptors expression and migration potential of tumor-infiltrating and peripheral-expanded 
Vgamma9Vdelta2 T cells from renal cell carcinoma patients, Journal of immunotherapy, 31 
(2008) 313-323. 
[123] A. Cordova, F. Toia, C. La Mendola, V. Orlando, S. Meraviglia, G. Rinaldi, M. 
Todaro, G. Cicero, L. Zichichi, P.L. Donni, N. Caccamo, G. Stassi, F. Dieli, F. Moschella, 
Characterization of human gammadelta T lymphocytes infiltrating primary malignant 
melanomas, PloS one, 7 (2012) e49878. 
[124] F. Toia, S. Buccheri, A. Anfosso, F. Moschella, F. Dieli, S. Meraviglia, A. Cordova, 
Skewed Differentiation of Circulating Vgamma9Vdelta2 T Lymphocytes in Melanoma and 
Impact on Clinical Outcome, PloS one, 11 (2016) e0149570. 
[125] F. Pages, A. Berger, M. Camus, F. Sanchez-Cabo, A. Costes, R. Molidor, B. Mlecnik, 
A. Kirilovsky, M. Nilsson, D. Damotte, T. Meatchi, P. Bruneval, P.H. Cugnenc, Z. 
Trajanoski, W.H. Fridman, J. Galon, Effector memory T cells, early metastasis, and survival 
in colorectal cancer, The New England journal of medicine, 353 (2005) 2654-2666. 
[126] M. Corvaisier, A. Moreau-Aubry, E. Diez, J. Bennouna, J.F. Mosnier, E. Scotet, M. 
Bonneville, F. Jotereau, V gamma 9V delta 2 T cell response to colon carcinoma cells, 
Journal of Immunology, 175 (2005) 5481-5488. 
[127] V. Groh, R. Rhinehart, H. Secrist, S. Bauer, K.H. Grabstein, T. Spies, Broad tumor-
associated expression and recognition by tumor-derived gamma delta T cells of MICA and 
MICB, Proceedings of the National Academy of Sciences of the United States of America, 96 
(1999) 6879-6884. 
[128] J. Ye, C. Ma, E.C. Hsueh, C.S. Eickhoff, Y. Zhang, M.A. Varvares, D.F. Hoft, G. Peng, 
Tumor-derived gammadelta regulatory T cells suppress innate and adaptive immunity 
through the induction of immunosenescence, Journal of Immunology, 190 (2013) 2403-2414. 
[129] D.R. Green, T. Ferguson, L. Zitvogel, G. Kroemer, Immunogenic and tolerogenic cell 
death, Nature Reviews Immunology, 9 (2009) 353-363. 
[130] Y. Ma, L. Aymeric, C. Locher, S.R. Mattarollo, N.F. Delahaye, P. Pereira, L. 
Boucontet, L. Apetoh, F. Ghiringhelli, N. Casares, J.J. Lasarte, G. Matsuzaki, K. Ikuta, B. 
Ryffel, K. Benlagha, A. Tesniere, N. Ibrahim, J. Dechanet-Merville, N. Chaput, M.J. Smyth, 
G. Kroemer, L. Zitvogel, Contribution of IL-17-producing gamma delta T cells to the 
efficacy of anticancer chemotherapy, The Journal of experimental medicine, 208 (2011) 491-
503. 
[131] S.R. Mattarollo, T. Kenna, M. Nieda, A.J. Nicol, Chemotherapy and zoledronate 
sensitize solid tumour cells to Vgamma9Vdelta2 T cell cytotoxicity, Cancer immunology, 
immunotherapy, 56 (2007) 1285-1297. 
[132] J.J. Fournie, H. Sicard, M. Poupot, C. Bezombes, A. Blanc, F. Romagne, L. Ysebaert, 
G. Laurent, What lessons can be learned from gammadelta T cell-based cancer 
immunotherapy trials?, Cellular & molecular immunology, 10 (2013) 35-41. 
[133] M. Wilhelm, V. Kunzmann, S. Eckstein, P. Reimer, F. Weissinger, T. Ruediger, H.P. 
Tony, Gammadelta T cells for immune therapy of patients with lymphoid malignancies, 
Blood, 102 (2003) 200-206. 
[134] F. Dieli, D. Vermijlen, F. Fulfaro, N. Caccamo, S. Meraviglia, G. Cicero, A. Roberts, 
S. Buccheri, M. D'Asaro, N. Gebbia, A. Salerno, M. Eberl, A.C. Hayday, Targeting human 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
55 
 
{gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-
refractory prostate cancer, Cancer research, 67 (2007) 7450-7457. 
[135] J. Bennouna, E. Bompas, E.M. Neidhardt, F. Rolland, I. Philip, C. Galea, S. Salot, S. 
Saiagh, M. Audrain, M. Rimbert, S. Lafaye-de Micheaux, J. Tiollier, S. Negrier, Phase-I 
study of Innacell gammadelta, an autologous cell-therapy product highly enriched in 
gamma9delta2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell 
carcinoma, Cancer immunology, immunotherapy, 57 (2008) 1599-1609. 
[136] S. Meraviglia, N. Caccamo, G. Guggino, M. Tolomeo, S. Siragusa, G. Stassi, F. Dieli, 
Optimizing tumor-reactive gammadelta T cells for antibody-based cancer immunotherapy, 
Current molecular medicine, 10 (2010) 719-726. 
[137] J.M. Lang, M.R. Kaikobad, M. Wallace, M.J. Staab, D.L. Horvath, G. Wilding, G. Liu, 
J.C. Eickhoff, D.G. McNeel, M. Malkovsky, Pilot trial of interleukin-2 and zoledronic acid to 
augment gammadelta T cells as treatment for patients with refractory renal cell carcinoma, 
Cancer immunology, immunotherapy, 60 (2011) 1447-1460. 
[138] P. Therasse, S.G. Arbuck, E.A. Eisenhauer, J. Wanders, R.S. Kaplan, L. Rubinstein, J. 
Verweij, M. Van Glabbeke, A.T. van Oosterom, M.C. Christian, S.G. Gwyther, New 
Guidelines to Evaluate the Response to Treatment in Solid Tumors, Journal of the National 
Cancer Institute, 92 (2000) 205-216. 
[139] D. Marquez-Medina, J. Salla-Fortuny, A. Salud-Salvia, Role of gamma-delta T-cells in 
cancer: another opening door to immunotherapy, Clinical & translational oncology, 14 (2012) 
891-895. 
[140] H. Kobayashi, Y. Tanaka, J. Yagi, Y. Osaka, H. Nakazawa, T. Uchiyama, N. Minato, 
H. Toma, Safety profile and anti-tumor effects of adoptive immunotherapy using gamma-
delta T cells against advanced renal cell carcinoma: a pilot study, Cancer immunology, 
immunotherapy, 56 (2007) 469-476. 
[141] M. Sakamoto, J. Nakajima, T. Murakawa, T. Fukami, Y. Yoshida, T. Murayama, S. 
Takamoto, H. Matsushita, K. Kakimi, Adoptive immunotherapy for advanced non-small cell 
lung cancer using zoledronate-expanded gammadeltaTcells: a phase I clinical study, Journal 
of immunotherapy, 34 (2011) 202-211. 
[142] A.J. Nicol, H. Tokuyama, S.R. Mattarollo, T. Hagi, K. Suzuki, K. Yokokawa, M. 
Nieda, Clinical evaluation of autologous gamma delta T cell-based immunotherapy for 
metastatic solid tumours, British journal of cancer, 105 (2011) 778-786. 
[143] V. Kunzmann, B. Kimmel, T. Herrmann, H. Einsele, M. Wilhelm, Inhibition of 
phosphoantigen-mediated gammadelta T-cell proliferation by CD4+ CD25+ FoxP3+ 
regulatory T cells, Immunology, 126 (2009) 256-267. 
[144] V. Kunzmann, M. Wilhelm, Anti-lymphoma effect of gammadelta T cells, Leukemia & 
lymphoma, 46 (2005) 671-680. 
[145] L.S. Lamb, Jr., P. Musk, Z. Ye, F. van Rhee, S.S. Geier, J.J. Tong, K.M. King, P.J. 
Henslee-Downey, Human gammadelta(+) T lymphocytes have in vitro graft vs leukemia 
activity in the absence of an allogeneic response, Bone marrow transplantation, 27 (2001) 
601-606. 
[146] M. Wilhelm, M. Smetak, K. Schaefer-Eckart, B. Kimmel, J. Birkmann, H. Einsele, V. 
Kunzmann, Successful adoptive transfer and in vivo expansion of haploidentical gammadelta 
T cells, Journal of translational medicine, 12 (2014) 45. 
[147] Y. Abe, M. Muto, M. Nieda, Y. Nakagawa, A. Nicol, T. Kaneko, S. Goto, K. 
Yokokawa, K. Suzuki, Clinical and immunological evaluation of zoledronate-activated 
Vgamma9gammadelta T-cell-based immunotherapy for patients with multiple myeloma, 
Experimental hematology, 37 (2009) 956-968. 
[148] J. Nakajima, T. Murakawa, T. Fukami, S. Goto, T. Kaneko, Y. Yoshida, S. Takamoto, 
K. Kakimi, A phase I study of adoptive immunotherapy for recurrent non-small-cell lung 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
56 
 
cancer patients with autologous gammadelta T cells, European journal of cardio-thoracic 
surgery, 37 (2010) 1191-1197. 
[149] H. Kobayashi, Y. Tanaka, J. Yagi, N. Minato, K. Tanabe, Phase I/II study of adoptive 
transfer of gammadelta T cells in combination with zoledronic acid and IL-2 to patients with 
advanced renal cell carcinoma, Cancer immunology, immunotherapy, 60 (2011) 1075-1084. 
[150] A. Noguchi, T. Kaneko, T. Kamigaki, K. Fujimoto, M. Ozawa, M. Saito, N. Ariyoshi, 
S. Goto, Zoledronate-activated Vgamma9gammadelta T cell-based immunotherapy is 
feasible and restores the impairment of gammadelta T cells in patients with solid tumors, 
Cytotherapy, 13 (2011) 92-97. 
[151] T. Izumi, M. Kondo, T. Takahashi, N. Fujieda, A. Kondo, N. Tamura, T. Murakawa, J. 
Nakajima, H. Matsushita, K. Kakimi, Ex vivo characterization of gammadelta T-cell 
repertoire in patients after adoptive transfer of Vgamma9Vdelta2 T cells expressing the 
interleukin-2 receptor beta-chain and the common gamma-chain, Cytotherapy, 15 (2013) 
481-491. 
[152] L. Martinet, R. Poupot, J.J. Fournie, Pitfalls on the roadmap to gammadelta T cell-
based cancer immunotherapies, Immunology letters, 124 (2009) 1-8. 
[153] M.O. Li, Y.Y. Wan, S. Sanjabi, A.K. Robertson, R.A. Flavell, Transforming growth 
factor-beta regulation of immune responses, Annual review of immunology, 24 (2006) 99-
146. 
[154] L. Martinet, Regulation of T cell effector responses by tumour stromal cells, Ph.D. 
Thesis. Immunology. University Toulouse III-Paul Sabatier, (2008) 1-167. 
[155] L. Martinet, S. Fleury-Cappellesso, M. Gadelorge, G. Dietrich, P. Bourin, J.J. Fournie, 
R. Poupot, A regulatory cross-talk between Vgamma9Vdelta2 T lymphocytes and 
mesenchymal stem cells, European journal of immunology, 39 (2009) 752-762. 
[156] A. Marten, M. von Lilienfeld-Toal, M.W. Buchler, J. Schmidt, Soluble MIC is elevated 
in the serum of patients with pancreatic carcinoma diminishing gammadelta T cell 
cytotoxicity, International journal of cancer., 119 (2006) 2359-2365. 
[157] N. Demotte, V. Stroobant, P.J. Courtoy, P. Van Der Smissen, D. Colau, I.F. Luescher, 
C. Hivroz, J. Nicaise, J.L. Squifflet, M. Mourad, D. Godelaine, T. Boon, P. van der Bruggen, 
Restoring the association of the T cell receptor with CD8 reverses anergy in human tumor-
infiltrating lymphocytes, Immunity, 28 (2008) 414-424. 
[158] M. Colonna, F. Navarro, T. Bellon, M. Llano, P. Garcia, J. Samaridis, L. Angman, M. 
Cella, M. Lopez-Botet, A common inhibitory receptor for major histocompatibility complex 
class I molecules on human lymphoid and myelomonocytic cells, The Journal of 
experimental medicine, 186 (1997) 1809-1818. 
[159] A. Okamoto, T. Nikaido, K. Ochiai, S. Takakura, M. Saito, Y. Aoki, N. Ishii, N. 
Yanaihara, K. Yamada, O. Takikawa, R. Kawaguchi, S. Isonishi, T. Tanaka, M. Urashima, 
Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression 
profiles of serous ovarian cancer cells, Clinical cancer research, 11 (2005) 6030-6039. 
[160] Z. Liu, I.E. Eltoum, B. Guo, B.H. Beck, G.A. Cloud, R.D. Lopez, Protective 
immunosurveillance and therapeutic antitumor activity of gammadelta T cells demonstrated 
in a mouse model of prostate cancer, Journal of Immunology, 180 (2008) 6044-6053. 
[161] D. Simoni, N. Gebbia, F.P. Invidiata, M. Eleopra, P. Marchetti, R. Rondanin, R. 
Baruchello, S. Provera, C. Marchioro, M. Tolomeo, L. Marinelli, V. Limongelli, E. 
Novellino, A. Kwaasi, J. Dunford, S. Buccheri, N. Caccamo, F. Dieli, Design, synthesis, and 
biological evaluation of novel aminobisphosphonates possessing an in vivo antitumor activity 
through a gammadelta-T lymphocytes-mediated activation mechanism, Journal of medicinal 
chemistry, 51 (2008) 6800-6807. 
[162] T. Yuasa, K. Sato, E. Ashihara, M. Takeuchi, S. Maita, N. Tsuchiya, T. Habuchi, T. 
Maekawa, S. Kimura, Intravesical administration of gammadelta T cells successfully 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
57 
 
prevents the growth of bladder cancer in the murine model, Cancer immunology, 
immunotherapy, 58 (2009) 493-502. 
[163] B.H. Beck, H.G. Kim, H. Kim, S. Samuel, Z. Liu, R. Shrestha, H. Haines, K. Zinn, 
R.D. Lopez, Adoptively transferred ex vivo expanded gammadelta-T cells mediate in vivo 
antitumor activity in preclinical mouse models of breast cancer, Breast cancer research and 
treatment, 122 (2010) 135-144. 
[164] P. Dokouhaki, M. Han, B. Joe, M. Li, M.R. Johnston, M.S. Tsao, L. Zhang, Adoptive 
immunotherapy of cancer using ex vivo expanded human gammadelta T cells: A new 
approach, Cancer letters, 297 (2010) 126-136. 
[165] E. Di Carlo, P. Bocca, L. Emionite, M. Cilli, G. Cipollone, F. Morandi, L. Raffaghello, 
V. Pistoia, I. Prigione, Mechanisms of the antitumor activity of human Vgamma9Vdelta2 T 
cells in combination with zoledronic acid in a preclinical model of neuroblastoma, Molecular 
therapy, 21 (2013) 1034-1043. 
[166] K. Sato, S. Kimura, H. Segawa, A. Yokota, S. Matsumoto, J. Kuroda, M. Nogawa, T. 
Yuasa, Y. Kiyono, H. Wada, T. Maekawa, Cytotoxic effects of gammadelta T cells expanded 
ex vivo by a third generation bisphosphonate for cancer immunotherapy, International journal 
of cancer., 116 (2005) 94-99. 
[167] D. Kabelitz, D. Wesch, E. Pitters, M. Zoller, Characterization of tumor reactivity of 
human V gamma 9V delta 2 gamma delta T cells in vitro and in SCID mice in vivo, Journal 
of Immunology, 173 (2004) 6767-6776. 
[168] T. Santolaria, M. Robard, A. Leger, V. Catros, M. Bonneville, E. Scotet, Repeated 
systemic administrations of both aminobisphosphonates and human Vgamma9Vdelta2 T cells 
efficiently control tumor development in vivo, Journal of Immunology, 191 (2013) 1993-
2000. 
[169] I. Benzaid, H. Monkkonen, E. Bonnelye, J. Monkkonen, P. Clezardin, In vivo 
phosphoantigen levels in bisphosphonate-treated human breast tumors trigger 
Vgamma9Vdelta2 T-cell antitumor cytotoxicity through ICAM-1 engagement, Clinical 
cancer research, 18 (2012) 6249-6259. 
[170] I. Benzaid, H. Monkkonen, V. Stresing, E. Bonnelye, J. Green, J. Monkkonen, J.L. 
Touraine, P. Clezardin, High phosphoantigen levels in bisphosphonate-treated human breast 
tumors promote Vgamma9Vdelta2 T-cell chemotaxis and cytotoxicity in vivo, Cancer 
research, 71 (2011) 4562-4572. 
[171] N.O. Hodgins, W.T. Al-Jamal, J.T.-W. Wang, A.C. Parente-Pereira, M. Liu, J. Maher, 
K.T. Al-Jamal, In vitro potency, in vitro and in vivo efficacy of liposomal alendronate in 
combination with γδ T cell immunotherapy in mice, Journal of controlled release, 241 (2016) 
229-241. 
[172] N.O. Hodgins, Wang, J.T-W., Costa, P.M., Parente-Pereira, A.C., Al-Jamal, W.T., 
Maher, J. & Al-Jamal, K.T., Investigating the effect of tumour location and liposomal 
alendronate on the in vivo tumour uptake of intravenously-injected γδ T cells in mice., (2017, 
submitted). 
[173] N.O. Hodgins, W.T. Al-Jamal, J.T. Wang, R. Klippstein, P.M. Costa, J.K. Sosabowski, 
J.F. Marshall, J. Maher, K.T. Al-Jamal, Investigating in vitro and in vivo alphavbeta6 integrin 
receptor-targeting liposomal alendronate for combinatory gammadelta T cell immunotherapy, 
Journal of controlled release, 256 (2017) 141-152. 
 
  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
58 
 
 
Graphical abstract 
